PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS

Abstract: A compound of formula (I), wherein R<1> represents C1-4alkyl; and R<2>, R<3>, R<4> and R<5> each independently represent hydrogen or substituents; or R<1> and R<2> together form a linking chain -(CH2)mOp, (wherein m is 2 to 4 and p is zero or 1) which chain may be optionally substituted by one or two C1-4alkyl groups; and Y represents a group of formula (a) wherein R<8> and R<9> independently represent hydrogen C1-6alkyl, optionally substituted arylC1-6alkyl or optionally heteroarylC1-6alkyl; R<10> represents an optionally substituted aryl or optionally substituted heteroaryl group; and Z represents -(CH2)n wherein n is 2 to 8 or -(CH2)qCH=CH(CH2)r where q and r independently represent 1 to 3; or a salt thereof. This compound is useful for treating a condition which requires modulation of dopamine D3 receptors and thus has potential as an antipsychotic agent.

Description: PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS The present invention relates to novel phenylpyirole derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular as antipsychotic agents. European Patent Application No. 241053, describes compounds of the formula : wherein A is an unsaturated 5-membered heterocyclic ring, such as 2,5-pyrrolyl, or 3,5- or 1,4- pyrazolyl; X is a nitrogen or carbon atom; Rι,R2, R3 are each hydrogen or alkyl; R4 is aryl, heteroaryl, arylcarbonyl or heteroaryl-carbonyl; R is selected from a variety of substituents and n is 0-4. The compounds are said to have antipsychotic properties. European Patent Application No. 259930 describes compounds of the formula : wherein A is an unsaturated 5-membered heterocyclic ring, such as 2,5-pyrrolyl, 1,4- pyrazolyl or 2,5-furyl; R is hydrogen, alkyl or optionally substituted phenyl; R is alkyl, alkenyl or forms a ring with the phenyl group; R^ is hydrogen, hydroxy or alkoxy; R^ is selected from a variety of substituents and n is 0-3. These compounds are also said to have antipsychotic properties. We have now found a novel class of 2-phenylpyrroles which exhibit dopamine antagonist activity and thus have potential as antipsychotic agents. In a first aspect the present invention provides compounds of formula (I) : formula (I) wherein R 1 represents Cj^alkyl; and R2, R3, R4 and R^ each independently represent hydrogen, halogen, Cj^alkyl, C^alkoxy, Cι_4alkoxyCι_4alkyl, Cj^alkylsulphonyl, trifluoromethylsulphonyl; optionally substituted arylsulphonyl, optionally substituted heteroarylsulphonyl, optionally substituted aralkylsulphonyl, optionally substituted heteroaralkylsulphonyl, nitro, cyano, amino, mono- or di-alkylamino, trifluoromethyl, trifluoromethoxy, hydroxyl, hydroxyalkyl, Cι.4alkylthio, Cι_4alkanoyl, Cι_4alkoxycarbonyl, or wherein R > and R? each independently represent hydrogen, Cι_4alkyl or Cj^alkoxyCi^alkyl, or NR6R7 forms a 3- to 8- membered fully saturated heterocyclic ring, a 5- to 8-membered partially saturated heterocyclic ring, or a 5- to 8-membered fully saturated heterocyclic ring which contains in addition to the nitrogen atom an oxygen or sulphur atom; or Rl and R^ together form a linking chain -(CH2) m Op; (wherein m is 2 to 4 and p is zero or 1) which chain may be optionally substituted by one or two Cι_4alkyl groups; and Y represents a group of formula : 10 8 H R R x / -C— N (a) wherein R 8 and R 9 independently represent hydrogen, Cχ_6alkyl, optionally substituted arylCι_6alkyl or optionally substituted heteroarylCι_6alkyl; R10 represents an optionally substituted aryl or optionally substituted heteroaryl group; and Z represents -(CH2) n wherein n is 2 to 8 or -(CH2)qCH=CH(CH2) r where q and r independently represent 1 to 3; and salts thereof. In the compounds of formula (I) an alkyl group or moiety may be straight or branched. Alkyl groups which may be employed include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl and any branched isomers thereof such as isopropyl, t-butyl, sec-pentyl, and the like. A halogen atom present in the compounds of formula (I) may be a fluorine, chlorine, bromine or iodine atom. Representative aryl groups or moieties present in any of the substituents R^, R^, R4, R5, R8 t R9 ? and R10 m compounds of formula (I) include phenyl, naphthyl, and tetrahydronaphthyl. Suitable examples of heteroaryl groups include both 5 and 6- membered heterocycles containing one or more oxygen, sulphur or nitrogen atoms, such as furyl, thienyl, pyrryl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyridazyl, pyrimidyl and pyrazyl. Suitable substituents for said aryl and heteroaryl groups include halogen, C^alkyl, Cj^alkoxy, Cι_4alkoxyCι_4alkyl, nitro, cyano, amino, mono- or dialkylamino, trifluoromethyl, trifluoromethoxy, hydroxy, hydroxyalkyl, Cι_4alkanoyl and Cι_4alkoxycarbonyl. 10 H R v / -N The ring v —.Z J in the group Y preferably has from 4 to 10, e.g. 5 to 8 ring members. Representative heterocyclic groups include pyrrolidinyl, piperidinyl, azacycloheptyl and azacyclooctyl. For the avoidance of doubt the azacycloheptyl and azacyclooctyl rings may also be named as hexahydroazepinyl and octahydroazocinyl respectively. When Rl and R^ together form a group -(0112) 111 0 0 wherein p is 1 it will be appreciated that the oxygen atom is attached to the phenyl ring at the R^ position : (CH 2 ) π R R When the (CH_2) m moiety is substituted by two Cι_4alkyl groups these are preferably substituted on the same carbon atom e.g. a gem-dimethyl substituenL In the group -Sθ2NR 6 R 7 , when NR 6 R 7 forms a 3- to 8- membered fully saturated heterocyclic ring this may be for example an azetidinyl, pyrrolidinyl, piperidinyl or azacycloheptyl ring. Examples of a 5- to 8-membered partially saturated heterocyclic ring include 1,2,3,6-tetrahydropyridinyl, and examples of a 5- to 8-membered fully saturated heterocyclic ring which contains in addition to the nitrogen atom an oxygen or sulphur atom include morpholinyl or thiomorpholinyl). In the compounds of formula (I) R* preferably represents methyl or ethyl. Preferably at least one of R^ to R^ is hydrogen, and the other substituents are selected from halogen, Cj^alkyl, C-^alkoxy, Cι_4alkylsulphonyl, phenylsulphonyl, benzylsulphon>l and -SO2NR6R 7 wherein R^ and R 7 represent Cj^alkyl (e.g. methyl, ethyl, n-propyl or iso-propyl) or C^aftravCi^alkvl (e.g. methoxyethyl), or NR^R 7 represents a ring selected from azetidinyl, pyrrolidinyl, piperidinyl, azacycloheptyl, 1,2,3,6-tetrahydropyridinyl, 4-morpholinyl or 4-thiomorpholinyl. In particular one of R^ to R^» e.g. R 4 , represents Cι_4alkylsulphonyl, phenylsulphonyl, benzylsulphonyl or a group -S02NR6R7 and the remaining substituents R2 to R5 are selected from hydrogen, halogen, Cι_2al yl and Cι_2al oxy. Thus, for example, R^ may be hydrogen, halogen e.g. bromine, methyl or methoxy and R^ and R$ may be hydrogen. R8 preferably represents hydrogen. R 9 preferably represents hydrogen or methyl. RIO preferably represents optionally substituted phenyl. Preferred substituents for the group RIO include halogen (e.g fluorine) Cι_4alkyl (e.g. methyl) and Cj^alkoxy (e.g. methoxy). Z preferably represents -(CH2) n wherein n is 3, 4 or 5, or -(CH2)qCH=CH(CH2) r where the sum of q and r is 2 or 3. Preferably the compounds of formula (I) are of the R configuration about the carbon atom in the group Y which is substituted by R 0. It will be appreciated that for use in medicine the salts of formula (I) should be physiologically acceptable. Suitable physiologically acceptable salts will be apparent to those skilled in the art and include for example acid addition salts formed with inorganic acids eg. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid; and organic acids eg. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulphonic, methanesulphonic or naphthalenesulphonic acid. Other non-physiologically acceptable salts eg. oxalates may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention. Also included within the scope of the invention are solvates and hydrates of compounds of formula (I). It will be appreciated that the compounds of formula (I) contain one or more asymmetric centres and will therefore exist in the form of optical isomers (enantiomers). The present invention includes within its scope all such enantiomers and mixtures, including racemic mixtures, thereof. In addition, all possible diastereomeric forms (individual diastereomers and mixtures thereof) of compounds of formula (I) are included within the scope of the invention. Particular compounds according to the invention include : 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-( 1 -(2-(R,S)-phenylpiperidinyl)-methyl)- 1H- pyrrole, 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-( 1 -(2-(R,S)-phenylpyrrolidinyl)-methyl)- 1H- pyrrole, 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R,S)-phenylazacycloheptyl)-methyl)-lH- pyrrole, 2-(3,5-dibromo-2-methoxyphenyl)-5-(l-(2-(R,S)-phenylazacycloheptyl)-methyl)-lH- pyrrole, 2-(2-methoxy-5-N,N-dimethylaminosulphonylphenyl)-5-[ 1 -(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R,S)-phenylazacycloheptyl)- methyl)- lH-pyrrole, 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R)-phenylazacycloheptyl)methyl)-lH- pyrrole 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(S)-phenylazacycloheptyl)methyl)-lH- pyrrole, 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R,S)-phenylazacycloheptyl)- methyl)- lH-pyrrole, 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R)-phenylazacycloheptyl)- methyl)- lH-pyrrole, 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(S)-phenylazacycloheptyl)- methyl)- lH-pyrrole, 2-(2-methoxy-5-dimethylaminosulphonylphenyl)-5-[l-(2-(R,S)-(4-fluorophenyl)- azacycloheptyl)methyl]- lH-pyrrole, 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)-(4-fluorophenyl)- azacycloheptyl)methyl]-lH-pyrrole, 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)-(4-methylphenyl)azacycloheptyl)- methyl]- lH-pyrrole), 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)-(4-methoxyphenyl)- azacycloheptyl)methyl]-lH-pyrrole, 2-(5-N,N-diethylaminosulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)-phenylazacycloheptyl)- methyl]- lH-pyrrole, 2-(2-methoxy-5-pyrrolidinylsulphonylphenyl)-5-[ 1 -(2-(R,S)-phenylazacycloheptyl)- methyl]- lH-pyrrole, 2-(2-methoxy-5-piperidinylsulphonylphenyl)-5-[l-(2-(R,S)-phenylazacycloheptyl)- methyl]- lH-pyrrole, 2-(2-methoxy-5-(4-morpholinyl)sulphonylphenyl)-5-[l-(2-(R,S)-phenylazacycloheptyl)- methyl]- lH-pyrrole, 2-(2-methoxy-5-(4-morpholinyl)sulphonylphenyl)-5-(l-(2-(R)-phenylazacycloheptyl)- methyl)- lH-pyrrole, 2-(2-methoxy-5-(4-morpholinyl)suphonylphenyl)-5-(l-(2-(S)-phenylazacycloheptyl)- methyl)- lH-pyrrole, 2-(2-methoxy-5-N,N-di-n-propylaminosulphonylphenyl)-5-[l-(2-(R,S)-phenyl- azacycloheptyl)methyl]- lH-pyrrole, 2-(2-methoxy-5-N,N-di-n-propylaminosuphonylphenyl)-5-(l-(2-(R)-phenyl- azacycloheptyl)methyl)- 1 H-pyrrole, 2-(2-methoxy-5-N,N-di-n-propylaminosuphonylphenyl)-5-(l-(2-(S)-phenyl- azacycloheptyl)methyl)-lH-pyrrole, 2-(2-methoxy-5-(4-thiomorpholinyl)sulphonylphenyl)-5-[l-(2-(R,S)- phenylazacycloheptyl)methyl]- lH-pyrrole, 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R)-phenylpiperidinyl)methyl)-lH-pyrrole, 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(S)-phenylpiperidinyl)methyl)-lH-pyrrole, (-)-2-(5-ethylsulphonyl-2-methoxyphenyl)-5-( 1 -(2-(R or S)-phenylpyrrolidinyl)methyl)- lH-pyrrole, (+)-2-(5-ethylsulphonyl-2-methoxyphenyl)-5-( l-(2-(R or S)-phenylpyrrolidinyl)methyl)- lH-pyrrole, 2-[5-(azetidinylsulphonyl)-2-methoxyphenyl]-5-[l-(2-(R,S)-phenylazacycloheptyl)- methyl]- lH-pyrrole, 2-[5-(bis-(2-methoxyethyl))aminosulphonyl-2-methoxyphenyl]-5-(l-(2-(R,S)-phenyl- azacycloheptyl)methyl)- lH-pyrrole, 2- { 5-[(N-ethyl-N-2-methoxyethyl)aminosulphonyl]-2-methoxyphenyl) }-5-[ 1 -(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, 2-(5-benzylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)-phenylazacycloheptyl) methyl]- lH-pyrrole, 2-(5-isopropylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)-phenylazacycloheptyl)methyl]- lH-pyrrole, 2-(2-methoxy-5-phenylsulphonylphenyl)-5-[l-(2-(R,S)-phenylazacycloheptyl)methyl]-lH- pyrrole, 2-[5-(3,6-dihydro-2H-pyridine-l-sulphonyl)-2-methoxyρhenyl]-5-[l-(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, and salts thereof. The present invention also provides a process for preparing compounds of formula (I) which process comprises : (a) carrying out a Mannich reaction with a compound of formula (II) : Formula π (wherein R!-R5 are as hereinbefore defined), and an amine of formula (III) : Formula III wherein R 1 ^ and Z are as hereinbefore defined; (b) carrying out a Vilsmeier reaction with a compound of formula (II) and an amide of formula (TV) : Formula (IV) wherein R 9 , R^ and Z are as hereinbefore defined; and reducing the intermediate product with, for example, sodium borohydride or cyanoborohydride; c) to prepare a compound of formula (I) in which R 8 and R 9 both represent hydrogen, reductive amination of a compound of formula (V) : Formula (V) with an amine of formula (UI); and optionally thereafter forming a salt of formula (I). The Mannich reaction according to process (a) may be effected according to conventional methods. Thus for example the cyclic amine of formula (UI) may first be reacted with formaldehyde and the product subsequently reacted with a compound of formula (II). The reaction is preferably effected in a protic solvent, for example an alcohol such as ethanol. An organic or inorganic acid, e.g. acetic acid may be employed as a catalyst. The Vilsmeier reaction according to process (b) may also be effected according to conventional methods. Thus, for example, the amide of formula (TV) may first be treated with phosphorus oxychloride (POCI3) and the resulting product subsequently reacted with a compound of formula (II) conveniently in a solvent such as dichloroethane or dichloromethane. The product of this reaction is then reduced with, for example, sodium borohydride or cyanoborohydride. The reduction may be carried out in a suitable solvent, for example dichloroethane, dichloromethane, methanol, ethanol, water or mixtures thereof. Reductive amination according to process (c) will generally be carried out using a reducing agent such as sodium borohydride or cyanoborohydride and in the presence of a Lewis acid such as titanium (IV) chloride. Reaction of a compound (V) with the amine may conveniently be effected in a solvent such as dichloromethane or dichloroethane. A compound of formula (II) may be prepared by cyclisation of a dicarbonyl compound of formula (VI) : Formula (VI) wherein R^-R^ are as hereinbefore defined. The reaction may be effected using an ammonium salt, e.g. ammonium acetate, in a solvent such as ethanol. (See, for example, C.G. Kruse et al., Heterocycles, vol 26, 3141, 1987). A compound of formula (VI) may itself be prepared by reacting the appropriate substituted benzoyl halide with a metallo derivative of a 2-(2-haloethyl)- 1 ,3-dioxolane, or 2-(2-haloethyl)-l,3-dioxane, followed by acid hydrolysis. Compounds of formula (HI) are available commercially or may be prepared by standard methods. A compound of formula (TV) may be prepared by reacting an amine of formula (HI) with acetic anhydride in formic acid. A compound of formula (V) may be prepared by carrying out a Vilsmeier reaction in which dimethylformamide is reacted with phosphorus oxychloride and the product reacted with a compound of formula (II), in a solvent such as dichloroethane, followed by acid hydrolysis. When a compound of formula (I) is obtained as a mixture of enantiomers these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column. Alternatively a compound of formula (I) may be prepared as a single enantiomer by employing a chiral amine in the synthesis, for example directly in process (a) or (c) or in the preparation of an amide for use in process (b). A chiral amine of formula (IE), (TV) or (V) may be prepared by resolving an enantiomeric mixture of the appropriate amine for example by coupling to a chiral auxiliary such as (S)-(+)-α-methoxyphenylacetic acid and separating the resulting diastereoisomers by chromatography. The auxiliary moiety may be removed to give the desired chiral amine. Thus for example the (S)-(+)-α- methoxyphenylacetyl moiety may be cleaved under basic conditions for example using methyl lithium in a solvent such as tetrahydrofliran or hexane. Compounds of formula (I) have been found to exhibit affinity for dopamine receptors, in particular D3 receptors, and are expected to be useful in the treatment of disease states which require modulation of such receptors, such as psychotic conditions. The therapeutic effect of currently available antipsychotic agents (neuroleptics) is generally believed to be exerted via blockade of D2 receptors; however this mechanism is also thought to be responsible for undesirable extrapyramidal side effects (eps) associated with many neuroleptic agents. Without wishing to be bound by theory, it has been suggested that blockade of the recently characterised dopamine D3 receptor may give rise to beneficial antipsychotic activity without significant eps. (see for example Sokoloff et al, Nature, 1990; 347: 146-151; and Schwartz et al, Clinical Neuropharmacology, Vol 16, No.4, 295-314, 1993). Preferred compounds of the present invention are therefore those which have higher affinity for dopamine D3 than dopamine D2 receptors (such affinity can be measured using standard methodology for example using cloned dopamine receptors). Said compounds may advantageously be used as selective modulators of D3 receptors. In particular compounds of formula (I) are dopamine D3 receptor antagonists and as such are of potential use as antipsychotic agents for example in the treatment of schizophrenia, schizo-affective disorders, psychotic depression and mama. Other conditions which may be treated by modulation of dopamine D3 receptors include dyskinetic disorders such as Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; depression; and drug (eg. cocaine) dependency. In a further aspect therefore the present invention provides a method of treating conditions which require modulation of dopamine D3 receptors, for example psychoses such as schizophrenia, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) or a physiologically acceptable salt thereof. The invention also provides the use of a compound of formula (I) or a physiologically acceptable salt thereof in the manufacture of a medicament for the treatment of conditions which require modulation of dopamine D3 receptors, for example psychoses such as schizophrenia. For use in medicine, the compounds of the present invention are usually administered as a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of formula (I) or a physiologically acceptable salt thereof and a physiologically acceptable carrier. The compounds of formula (I) may be administered by any convenient method, for example by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly. The compounds of formula (I) and their physiologically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges. A liquid formulation will generally consist of a suspension or solution of the compound or physiologically acceptable salt in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring or colouring agent A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule. Typical parenteral compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration. Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluorochlorohydrocarbon. The aerosol dosage forms can also take the form of a pump-atomiser. Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter. Compositions suitable for transdermal administration include ointments, gels and patches. Preferably the composition is in unit dose form such as a tablet, capsule or ampoule. Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I) or a physiologically acceptable salt thereof calculated as the free base. The physiologically acceptable compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 500 mg, preferably between 10 mg and 400 mg, e.g. between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound of the formula (I) or a physiologically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more. The invention is further illustrated by the following non-limiting examples : Description 1 2-(R,S)-Phenylazacycloheptane To a solution of l-aza-2-methoxy-l-cycloheptene (50.9 g) in benzene (600 ml) under argon was added phenyl magnesium bromide (300 ml of a 3M solution in ether) and the mixture was heated at reflux for 4 h. The reaction mixture was cooled (ice/water) and LiAlH4 (16.9 g) was added portion wise. The mixture was then heated at reflux for 5 h, cooled to room temperature and poured onto crushed ice. The resultant slurry was basified with aqueous 10% sodium hydroxide and filtered through kieselguhr, which was then washed with ether. The layers were separated and the aqueous fraction was further extracted with ether. The combined ether layers were dried (sodium sulphate) and evaporated to dryness in vacuo to give an orange-gold liquid, which on distillation (0.5 mm Hg) gave the title compound as a colourless liquid (46.43 g, 66%), bp 82-90°C. !H NMR (CDCI3) δ: 1.50 - 2.09 (8H, broad m), 2.75 - 2.95 (1H, m), 3.06 - 3.24 (1H, m), 3.65 - 3.81 (1H, dd, J=4,10 Hz), and 7.13 - 7.45 (5H, m). The following compounds were prepared according to the general method of Description 1: 2-(R,S)-(4-Fluorophenyl)azacycloheptane *H NMR (CDCI3) δ: 1.62 - 1.98 (8H, m), 2.79 - 2.89 (1H, m), 3.08 - 3.17 (1H, m), 3.71 - 3.80 (1H, m), 6.95 - 7.02 (2H, m), and 7.26 - 7.33 (2H, m). 2-(R,S)-(4-Methylphenyl)azacycloheptane !H NMR (CDCI3) δ: 1.50 - 2.0 (8H, m), 2.32 (3H, s), 2.78 - 2.87 (1H, m), 3.09 - 3.17 (1H, m), 3.71 (1H, m), 7.12(2H, d, J=8 Hz), and 7.24 (2H, d, J=8 Hz) 2-(R )-(4-MethoxyphenyI)azacycloheptane !H NMR (CDCI3) δ: 1.61 - 1.97 (8H, m), 2.78 - 2.87 (1H, m), 3.09 - 3.16 (1H, m), 3.67 - 3.72 (1H, m), 3.79 (3H, s), 6.84 (2H, d, J=9 Hz), and 7.26 (2H, d, J=9Hz) Descriptions (2a) and (2b) N-[(S)-α-methoxyphenylacetyl]-2-(R)-phenylazacycIoheptane (D2a) and N-[(S)-α- methoxyphenylacetyl)-2-(S)-phenylazacycloheptane (D2b) To a solution of (S)-(+)-α-methoxyphenylacetic acid (3.65 g, 22 mmol) in dichloromethane (35 ml) and dimethylformamide (1 drop) was added oxalyl chloride (2.8 ml, 33 mmol), dropwise, under argon at room temperature. After 2 h the volatiles were removed in vacuo and the residue was dissolved in dichloromethane (90 ml). The solution was added at room temperature, with vigorous mechanical stirring, to a solution of 2- (R,S)-phenylazacycloheptane (3.88 g, 22 mmol) in dichloromethane (90 ml) and 5% aqueous NaOH (190 ml). After 0.25 h the layers were separated and the organic layer was washed with water, dried, and evaporated in vacuo to give a colourless oil. Chromatography on silica gel eluting with 20-30% ethyl acetate/pentane afforded the title compounds [total yield 88%] as two diastereoisomers: the faster eluting isomer (D2a) (3.18g, 45%) *H NMR (CDCI3) exists as two conformers, δ: 0.80 - 1.06 (broad m) and 1.14 - 1.47 (broad m) (together IH), 1.55 - 1.90 (6H, broad m), 2.17 - 2.40 (IH, broad m), 2.80 - 2.97 (IH, broad m), 3.14 (s) and 3.47 (s) (together 3H), 3.90 - 4.05 (broad d, J=13 Hz) and 4.29 - 4.45 (broad d, J=13 Hz) (together IH), 4.98 (s) and 5.08 (s) (together IH), 5.12 (q, J=5 Hz) and 5.42 (q, J=5 Hz) (together IH), and 7.02 - 7.48 (10H, m). and the slower eluting isomer (D2b) (3.04 g, 43%) *H NMR (CDCI3) exists as two conformers, δ: 0.54 - 0.79 (broad m) and 1.10 - 1.45 (broad m) (together IH), 1.50 - 1.98 (6H, broad m), 2.13 - 2.49 (broad m) and 2.76 - 3.10 (broad m) (together 2H), 3.18 (s) and 3.40 (s) (together 3H), 3.78 (broad d, J= 16 Hz) and 4.58 (broad d, J=16 Hz) (together IH), 4.64 (s) and 5.03 (s) (together IH), 4.72 (q, J=5 Hz) and 5.64 (q, J=5 Hz) (together IH), and 6.94 - 7.50 (10H, m). Description 3 2-(R)-Phenylazacycloheptane To a solution of the faster eluting amide diastereoisomer (D2a) (3.18 g, 9.8 mmol) in dry tetrahydrofuran (32 ml) under argon at room temperature was added methyl lithium (25.4 ml, 4 eqiv. of a 1.5 M solution in ether). After 40 min. the reaction was basified with saturated aqueous potassium carbonate and extracted into ether. The ether fraction was extracted into aqueous 5N hydrochloric acid, rebasified, and extracted into ether. It was dried (sodium sulphate) and evaporated to dryness in vacuo to give the crude product as a yellow oil, which was distilled using a Kugelrohr to give the title compound as a colourless oil (0.67g, 39%), bp 100°C (0.3 mm Hg), [α] 20 D + 35° (c, 0.89%, MeOH), ee > 92.6% by HPLC on a Chiralcel OJ column using hexane/ethanol as the eluant !H NMR (CDCI3) δ: 1.54 - 2.04 (8H, broad m), 2.78 - 2.96 (IH, m), 3.07 - 3.23 (IH, m), 3.68 - 3.84 (IH, m), and 7.18 - 7.47 (5H, m). The stereochemistry was identified by comparison with the opposite enantiomer (product of Description 4) Description 4 2-(S)-Phenylazacycloheptane The title compound was obtained in 33% yield from the slower eluting diastereoisomer (D2b) (3.04 g, 9.4 mmol) using a procedure similar to Description 3, [α] 20 o -30.8° (c, 0.9 %, MeOH), ee > 98.8% by HPLC on a Chiralcel OJ column using hexane/ethanol as the eluant J H NMR (CDCI3) δ: 1.49 - 2.10 (8H, broad m), 2.76 - 2.97 (IH, m), 3.05 - 3.23 (IH, m), 3.68 - 3.84 (IH, m), and 7.12 - 7.50 (5H, m). The stereochemistry was confirmed by single crystal X-ray structure determination of the hydrobromide salt The following compounds were prepared according to the general method of Examples 2a, 2b, 3 and 4: N-[(S)-α-Methoxyphenylacetyl]-2-(R)-phenylpiperidine and N-[(S)-α- methoxyphenylacetyl]-2-(S)-phenylpiperidine Faster eluting isomer (6.52 g; 31%), !H NMR (CDCI3) δ: 1.22 - 1.91 (5H, broad m), 2.15 - 2.48 (IH, broad m), 2.56 - 2.79 (IH, broad t, J=13 Hz), 3.55 (3H, broad s), 3.73 - 4.00 (IH, broad m), 5.18 (IH, s), 5.82 - 6.11 (IH, broad m), and 7.05 - 7.62 (10H, m). Slower eluting isomer (6.0 g, 29%),*H NMR<CDCl3) exists as two conformers, δ: 1.21 - 1.63 (4H, broad m), 1.71 - 1.94 (broad m) and 2.09 - 2.22 (broad m) (together IH), 2.28 - 2.45 (broad m) and 2.51 - 2.85 (broad m) (together 2H), 3.44 (s) and 3.56 (s) (together 3H), 3.90 (d, J=12 Hz) and 4.63 (d, J=12 Hz) (together IH), 4.95 (s) and 5.18 (s) (together IH), 5.18 (broad s) and 6.01 (broad s) (together IH), and 7.02 - 7.57 (10H, m). 2-(R)-Phenylpiperidine Prepared from faster eluting amide isomer. [α] 2 ^ +26.30° (c 0.9%, methanol), *H NMR (CDCI3) δ: 1.38 - 1.90 (6H, broad m), 2.66 - 2.81 (IH, dt, J=12,3 Hz), 3.06 - 3.21 (IH, d, J=12 Hz), 3.46 - 3.58 (IH, dd, J=12.3 Hz), and 7.10 - 7.38 (5H, m). The stereochemistry was confirmed by single crystal X-ray structure determination of the hydrobromide salt 2-(S)-Phenylpiperidine Prepared from slower eluting amide isomer. [α] 2 ^ D -24° (c 0.9% in methanol) !H NMR (CDCI3) δ: 1.33 - 1.90 (6H, broad m), 2.63 - 2.80 (IH, dt J=12.3 Hz), 3.03 - 3.20 (IH, d, J=12 Hz), 3.44 -3.58 (IH, dt J=10.2 Hz), and 7.09 - 7.38 (5H, m). The stereochemistry was confirmed by comparison with the opposite enantiomer (above). N-[(S)-α-MethoxyphenylacetyI]-2-(R)-phenylpyrrolidine and N-[(S)-α- Methoxyp enylacet l)-2-(S)-phenylpyrrolidine Faster eluting isomer (5.19 g, 43%) H NMR (CDCI3) exists as two conformers, δ: 1.70 - 1.88 (3H, broad m); 2.07 - 2.37 (IH, broad m); 3.14 (s) and 3.45 (s) (together 3H), 3.60 (broad t J=7 Hz) and 3.77 (broad t J=7 Hz), (together 2H), 4.69 (s) and 4.97 (s) (together IH), 5.18 - 5.30 (IH, m), and 6.72 - 7.52 (10H, m). Slower eluting isomer (4.17g, 35%) !H NMR (CDCI3) exists as two conformers, δ: 1.68 - 1.90 (3H, broad m), 2.07 - 2.25 (IH, m), 3.05 (s) and 3.43 (s) (together 3H), 3.50 - 3.98 (2H, m), 4.43 (s) and 4.91 (s) (together IH), 4.74 (broad d, J=8 Hz) and 5.25 (broad d, J=8 Hz) (together IH), and 7.1 - 7.46 (10H, m). (+)-2-Phenylpyrrolidine Prepared from faster eluting amide isomer. [α]20 D +38.2° (c 1.0% in methanol), IH NMR (CDCI3) δ: 1.54 - 2.0 (3H, m), 2.08 - 2.27 (IH, m), 2.9 - 3.08 (IH, m), 3.12 - 3.28 (IH, m), 4.10 (IH, t, J=8 Hz), and 7.12 - 7.42 (5H, m). (-)-2-Phenylpyrrolidine Prepared from slower eluting amide isomer. [α]20 D -24.9° (c 0.9% in methanol) IH NMR (CDCI3) δ: 1.53 - 1.93 (3H, m), 2.00 - 2.20 (IH, m), 2.84 - 3.02 (IH, m), 3.08 - 3.22 (IH, m), 4.03 (IH, t, J=7 Hz), and 7.08 - 7.40 (5H, m). Description 5 N-Formyl-2-(R,S)-phenylazacycloheptane To a mixture of, 98-100% formic acid (30 ml) and acetic anhydride (100 ml) was added 2- (R,S)-phenylazacycloheptane, (10 g, 57.1 mmol) and the mixture warmed to 70°C for 2 h. The reaction mixture was then cooled and evaporated to dryness in vacuo and the residue was partitioned between ether and saturated aqueous potassium carbonate. The ether layer was separated and evaporated to dryness in vacuo to afford the title compound (11.24 g; 97%) as a mixture of E Z isomers. !H NMR (CDCI3) exists as two conformers; δ 1.2-2.1(7H, m), 2.3-2.6 (1 H, m), 2.8 (t, J=12 Hz) and 3.3 (t J=12 Hz) (together IH), 3.65 (broad d, J=12 Hz) and 4.24 (broad d, J=12 Hz) (together IH), 4.67 (q, J=7 Hz) and 5.3 (q, J=7 Hz) (together IH), 7.13-7.45, (5H, m), 8.15 (s) and 8.3 (s) (together IH). The following compounds were prepared according to the general method of Description 5: N-Formyl-2-(R)-phenylazacycloheptane *H NMR (CDCI3) exists as two conformers, δ: 1.19 - 2.09 (7H, m), 2.39 (m) and 2.57 (m) (together IH), 2.81 (t, J=13 Hz) and 3.34 (t, J=13 Hz) (together IH), 3.68 (broad d, J=13 Hz) and 4.24 (broad d, J=13 Hz) (together IH), 4.68 (q, J=7 Hz) and 5.31 (q, J=7 Hz) (together IH), 7.13 - 7.50 (5H, m), 8.15 (s) and 8.29 (s) (together IH). N-Formyl-2-(S)-phenylazacycIoheptane !H NMR (CDCI3) exists as two conformers, δ: 1.26 - 2.12 (7H, m), 2.36 (m) and 2.57 (m) (together IH), 2.81 (dt, J=13,l Hz) and 3.34 (dt, J=13,l Hz) (together IH), 3.70 (broad d, J=13 Hz) and 4.25 (broad d, J=13 Hz) (together IH), 4.69 (q, J=5 Hz) and 5.32 (q, J=5 Hz) (together IH), 7.13 - 7.45 (5H, m), 8.16 (s) and 8.29 (s) (together IH). N-Formyl-2-(R,S)-(4-fluorophenyl)azacycloheptane IH NMR (CDCI3) δ: 1.27 - 1.54 (2H, m), 1.62 - 1.95 (5H, m), 2.27 - 2.38 (m) and 2.47 - 2.59 (m) (together IH), 2.72 - 2.83 (m) and 3.25 - 3.35 (m) (together IH), 3.64 - 3.76 (m) and 4.19 - 4.24 (m) (together IH), 4.62 - 4.69 (m) and 5.23 - 5.30 (m) (together IH), 6.95 - 7.10 (2H, m), 7.13 - 7.33 (2H, m), and 8.14 (s) and 8.26 (s) (together IH). Description 6 2-Methoxy-5-(N^-di-n-propylaminosulphonyl)benzoic acid To a solution of di-n-propylamine (25 ml) in water (200 ml), cooled to 10 °C, was added in portions 5-chlorosulphonyl-2-methoxybenzoic acid [prepared as described by W. Liebenow et al. Ger. Offen 2,721,643 (Chem. Abs. 90, 103673J)] (15g, 0.06 mol). The solution was stirred for 1 h, and then acidified with 5N hydrochloric acid. The resulting product was filtered, washed with hexane and recrystallised from ethyl acetate/hexane to give the title compound (9g; 50 %) as colourless microcrystals, mp 105 °C, (Found C, 52.93; H, 6.45; N, 4.49. C14H21NO5S requires C, 53.32; H, 6.71; N, 4.44%). The following compounds were prepared by the general method of Description 6: 5-(N,N-dimethylaminosulphonyl)-2-methoxybenzoic acid, mp 138-140°C 5-(N,N-diethylaminosulphonyl)-2-methoxybenzoic acid, mp 112-3°C 2-methoxy-5-(l-pyrrolidinylsulphonyl)benzoic acid, mp 145-146°C (ethyl acetate) 2-methoxy-5-(l-piperidinylsulphonyl)benzoic acid, mp 156-158°C, 2-methoxy-5-(4-morpholinylsulphonyl)benzoic acid, mp 181-183°C 2-methoxy-5-(4-thiomorpholinylsulphonyl)benzoic acid, mp 182-185°C 5-(l-azetidinylsulphonyl)-2-methoxybenzoic acid, mp 175-176°C 5-[(bis-(2-methoxyethyl))aminosulphonyl]-2-methoxybenzoic acid IH NMR (CDCI3) δ: 3.3 (6 H, s), 3.45 (4 H, t J = 5.4 Hz), 3.55 (4 H, t J = 5.4 Hz), 4.13 (3 H, s), 7.15 (IH, d, J = 8.8 Hz), 8.05 (IH, d,d, J = 8.8, 2.4 Hz), and 8.58 (IH, d, J = 2.4 Hz). Description 7 3-{3-[2-(l,3-Dioxolanyl)]propionyl}-4-methoxy-N^I-dimethylbenzenesulphonamide 5-(N,N-Dimethylaminosulphonyl)-2-methoxybenzoic acid (6.89 g; 26.6 mmol) in dichloromethane (50 ml) was treated with oxalyl chloride (5.0 ml ; 53.2 mmol) and one drop of dimethylformamide under an atmosphere of argon with continous stirring for 1 h. The solution was evaporated in vacuo and azeotroped with toluene (2x 50 ml). Trituration with hexane gave the acid chloride (6.8 g; 87%) as a colourless solid used without further purification. To dry magnesium (0.83 g, 34.6 mmol) in anhydrous tetrahydrofuran (10 ml) under an atmosphere of argon was added, dropwise, 2-(2-bromoethyl)-l,3-dioxolane (5.30 g, 29.3 mmol) at such a rate to maintain the temperature between 27°C and 30°C. After addition was complete the mixture was allowed to stir for 0.5 h at ambient temperature. This mixture was transfered dropwise over 0.5 h to anhydrous cuprous bromide (4.2g 29.3 mmol) at 0°C under an atmosphere of argon. The resulting dark mixture was stirred at 0°C for 0.75 h, and then cooled to -75°C. A solution of the dried acid chloride (above) in tetrahydrofuran (50 ml) was added dropwise at -75°C~67°C over 0.5 h. The final mixture was stirred for 1 h. at -75°C , allowed to reach ambient temperature over 0.75 h, and stirred for a further 1 h. The mixture was poured into 10% aqueous citric acid (200 ml) and ethyl acetate (200 ml) and stirred for 0.2 h. The mixture was allowed to settle and then was filtered through kieselguhr. The filtrate was separated and the aqueous layer was further extracted with ethyl acetate (3x 100 ml). The combined organic extracts were dried over sodium sulphate, filtered and evaporated in vacuo to a thick gum. The gum was extracted with dichloromethane (100 ml ) and filtered. The filtrate was evaporated in vacuo to an oil, which was chromatographed on silica, eluting with 1-20% ethyl acetate in dichoromethane to give the tide compound as colourless microcrystals (5.17g; 66%), mp 114-115°C, (Found: C, 52.15; H, 5.99; N,4.08. Cι 5 H 2 ιNO 6 S requires C, 52.47; H, 6.16; N,4.08%), tn/z 343.1089. C 15 H 2 ιNO 6 S requires M+ 343.1089 Description 8 4-Methoxy-3-(l,4-dioxobutyI)-N,N-dimethylbenzenesulp onamide A solution of 3-{3-[2-(l,3-dioxolanyl)]propionyl}-4-methoxy-N,N- dimethylbenzenesulphonamide (1.72 g, 5 mmol) was dissolved in tetrahydofuran (10 ml) and 2N hydrochoric acid (10 ml) and heated at reflux for 2 h under an atmosphere of argon. The mixture was diluted with water (50 ml) and extracted with ethyl acetate (3x 100 ml). The combined organic extracts were washed with water (10 ml), brine (50 ml) and dried over sodium sulphate. The dried extract was filtered and evaporated in vacuo to give the title compound as an oil. (1.45 g; 99%), which was used without further purification. Description 9 2-[2-Methoxy-5-(N^-dimethylaminosulphonyl)phenyI]-lH-pyιτole 4-Methoxy-3-(l,4-dioxobutyl)-N,N-dimethylbenzenesulphonamide (1.45 g; 5 mmol) was added to ethanol (20 ml) containing ammonium acetate (2g) and heated at reflux under an atmosphere of argon for 2 h. The mixture was evaporated to one quarter volume, diluted with water (20 ml ), saturated aqueous potassium carbonate (20 ml), and extracted with ethyl acetate (3 x 80 ml). The combined extracts were washed with water (20 ml), brine (50 ml) and dried over sodium sulphate. The dried extracts were filtered and evaporated in vacuo to give a low melting solid. Chromatography on silica, eluting with dichloromethane, gave the title compound (0.72 g; 50 %), as colourless microcrystals, mp 129-130°C, (Found: C, 55.73; H, 5.73; N, 9.87. Ci3H 16 N 2 O S requires C, 55.70; H, 5.75; N, 9.99%). The following compounds were prepared according to the general methods of Descriptions 7-9: 2-(5-N,N-DiethylaminosulphonyI-2-methoxyphenyl-)-lH-pyrrole mp 139-140°C (ether), (Found: C, 58.30; H, 6.39; N, 9.15. C15H20N2O3S requires C, 58.42; H, 6.54; N,9.08%). 2-[2-Methoxy-S-(l-pyιτoIidinyl)sulphonylphenyl lH-pyrrole mp 118-121 0 C (ether), Found: C, 58.76; H, 5.87; N, 9.13. Ci 5 H 18 N 2 O3S requires C, 58.80; H, 5.92; N, 9.14%, m/z 306.1044. C 15 H 18 N 2 O3S requires M+ 306.1064 2-(S-(l-Piperidinyl)sulphonyl-2-methoxyphenyl)-lH-pyιτole mp 137-139°C (ether), Found: C, 59.86; H, 6.25; N, 8.67. C16H20N2O3S requires C, 59.98; H, 6.29; N,8.74%, m/z 320.1212. C 16 H 2 oN2θ S requires M+ 320.1230) 2-(5-IsopropylsulphonyI-2-methoxyphenyl)-lH-pyrrole Mass spectrum: Found M+279.0934; Ci4H 17 NO3S requires M+ 279.0929 Description 10 2-(2-(2-Methoxy-5-(N,N-di-n-propylamino)sulphonyl)benzoyl)ethyl-l-3-dioxane A solution of 2-methoxy-5-(N,N-di-n-propylaminosulphonyl)benzoic acid (7.4 g, 2.35 mmol) in anhydrous dichloromethane (50 ml), under an atmosphere of argon, was treated with oxalyl chloride (4.0 ml) and dimethylformamide (3 drops). The mixture was allowed to stir for 1 h and then was evaporated to dryness in vacuo. The resulting oil was dissolved in tetrahydrofuran (120 ml), under argon, and cooled to -70°C. A solution of 0.89 M 2-(2-bromomagnesiumethyl)-l,3-dioxane (43 ml, 2.35 mmol) (prepared from addition of 2-(2-bromoethyl)-l,3-dioxane to magnesium in tetrahydrofuran at reflux) was added dropwise over 0.5 h. The mixture was stirred at -70°C for a further 0.5 h, and then then allowed to warm up to ambient temperature over the next 1.5 h. The mixture was cooled to -10°C, and 10% aqueous citric acid (100 ml) was added dropwise. The resulting mixture was partitioned between water (100ml) and dichloromethane (150 ml). The aqueous layer was further extracted with dichloromethane (2x 100 ml) and the combined organic layers were washed with water (100 ml), 1.0 M NaOH (100 ml), water (100 ml), brine (100 ml ) and then dried over sodium sulphate. The dried extracts were filtered and evaporated to dryness in vacuo to yield the title compound as an oil (7.2g; 81% ), which was used without further purification. Description 11 3-(2-Methoxy-5-(N^S-di-n-propylaminosulphonyl)benzoyl)-l,l-dimethoxypropane A solution of 2-(2-(2-methoxy-5-(N,N-di-n-propylamino)sulphonyl)benzoyl)ethyl-l-3- dioxane in methanol (200 ml) containing p-toluenesulphonic acid (0.4 g) was heated under reflux for 2.5 h. The solution was cooled , neutralised with saturated aqueous sodium bicarbonate (50 ml) and evaporated to one quarter volume. The resulting mixture was partitioned between water (100 ml) and dichloromethane (150 ml). The aqueous layer was further extracted with dichloromethane (2x 100 ml) and the combined organic layers were washed with water (100 ml), brine (100 ml), and dried over sodium sulphate. The dried extracts were filtered and evaporated to dryness in vacuo to yield the title compound (6.8g; 98%), which was used without further purification. Description 12 3-(2-Methoxy-5-(NJ -di-n-propylaminosulphonyl)benzoyl)propanal A solution of 3-(2-methoxy-5-(N,N-di-n-propylaminosulphonyl)benzoyl)-l,l-dimethoxy propane in tetrahydrofuran (80 ml ) was treated with IN hydrochloric acid (80 ml) and stirred at room temperature for 2 h. The solution was evaporated in vacuo to one quarter volume and extracted with ethyl acetate (150 ml). The organic extract was washed with water (100 ml), brine (100 ml ) and dried over sodium sulphate. The dried extracts were filtered and evaporated to dryness in vacuo to yield the title compound (6.0g; 97%), which was used without purification. Description 13 2-(2-Methoxy-5-(N^«ϊ-di-n-propyIaminosulphonyl)phenyl)-lH-pyrrole A solution of 3-(2-methoxy-5-(N,N-di-n-propylaminosulphonyl)benzoyl)propanal in tetrahydrofuran (40 ml) was added to a suspension of ammonium acetate (8.0 g) in ethanol (40 ml), under argon, and warmed to gentle reflux for 1 h and then left to stir at room temperature for 17 h. The mixture was evaporated to one quarter volume and basified with saturated aqueous potassium carbonate. The resulting mixture was partitioned between water (100ml) and dichloromethane(150 ml). The aqueous layer was further extracted with dichloromethane (2x 100 ml) and the combined organic layers were washed with water (100 ml), brine (100 ml), and dried over sodium sulphate. The dried extract was filtered and evaporated to dryness in vacuo to give an oil, which was chromatographed on silica, eluting with 1-2% methanol in dichloromethane to give the title compound (2.6 g; 36%) as a colourless crystalline solid, mp 95-96°C (ether), (Found: C, 60.51; H, 7.01; N, 8.33. C17H24N2O3S requires C, 60.69; H, 7.19; N, 8.33%), m/z 336.1517. C17H24N2O3S requires M+ 336.1512 The following compounds were prepared by the general method of Descriptions 10-13: 2-[5-(l-AzetidinyIsuIphonyI)-2-methoxyphenyI]-lH-pyrroIe mp 108-109°C (ether), Found: m/z 292.0868. C14H16N2O3S requires M+ 292.0882 2-(2-Methoxy-5-[(bis-(2-methoxyethyl))aminosulphonyl]phenyl-lH-pyrrole mp 58-62 0 C (50%). *H NMR (CDCI3) δ: 3.3 (6H s), 3.4 (4 H, J = 4 Hz), 3.55 (4 H, t, J = 5.4 Hz), 4.05(3 H, s), 6.03 (1 H, m), 6.70 (1 H, m), 6.90 (1 H, m), 7.03 (1 H, d, J = 8.8 Hz), 7.60 (1 H, dd, J = 8.8, 2.4 Hz), 8.08 (1 H, d, J = 2.4 Hz), and 9.75 (IH, broad s). 2-{5-[(N-Ethyl-N-(2-methoxyethyl)amino)sulphonyl]-2-methoxyphenyl)}-lH-pyrrole mp 84-85°C. (Found C56.58; H, 6.38; N, 8.45%. Cι 6 H 2 2N2θ4S requires C, 56.79; H, 6.55; N, 8.28 %), m/z 338.1312. C16H22N2O4S requires M+ 338.1299 2-(5-BenzylsuIphonyl-2-methoxyphenyl)-lH-pyrrole NMR δ (CDCI3) 4.00 (3H, s), 4.30 (2H, s), 6.30 (IH, m), 6.50 (IH, m), 6.90 (IH, m), 6.95 (IH, d, J = 9Hz), 7.05-7.40 (6H, m), 7.80 (IH, d, J=lHz), 9.60 (IH, broad s). 2-[5-(l^,6-Tetrahydropyridine-l-sulphonyl)-2-methoxyphenyl]-lH-pyrrole NMR δ (CDCI3) 2.20 (2H, bm), 3.20 (2H, t J = 6Hz), 3.60 (2H, m), 4.05 (3H, s), 5.55- 5.85 (2H, m), 6.30 (IH, m), 6.70 (IH, m), 6.90 (IH, m), 7.05 (IH, d, J = 9Hz), 7.60 (IH, dd, J=lHz, 9Hz), 8.00 (IH, d, J=lHz), 9.75 (IH, broad s). 2-(2-Methoxy-5-(4-morphoIinyl)sulphonylphenyl)-lH-pyrrole mp 149-151 0 C (ether), Found: C55.13; H, 5.68; N, 8.24; Ci5H 18 N2θ 4 S .0.25H 2 0 requires C, 55.13; H, 5.67; N, 8.58%, m/z 322. Ci5HιgN2θ4S requires M+ 322. 2-(2-Methoxy-5-(4-thiomorpholinyl)sulphonylphenyl)-lH-pyrrole mp 162-163°C (ether), Found: C, 52.86; H, 5.30; N, 8.13. Cχ5HιgN2θ3S2 requires C, 53.23; H, 5.36; 8.28%, m/z 338. Ci 5 HigN 2 O3S2 requires M+ 338. Description 14 5-[(N-EthyI-N-(2-methoxyethyI)amino)sulphonyl]-2-methox benzoic add 5-Chlorosulphonyl-2-methoxybenzoic acid (25g, 0.1 mol) was added, portionwise, to a solution of N-ethyl-N-(2-methoxyethyl)amine (prepared as described by L. H. Craine et al. J. Am. Chem. Soc, 105, 7252-7255) (10.3 g, 0.1 mol) in H2O (200 ml) containing triethylamine (28 ml), at 10 °C. The solution was stirred for 1 h and then acidified with 5N hydrochloric acid. The resulting product was filtered, washed with hexane and recrystallised from ethyl acetate/hexane to give the title compound (17g; 54 %) as colourless microcrystals, mp 93.5-94.5 °C. (Found: C, 49.06; H,5.82; N, 4.68 %. Ci3H 19 NO 6 S requires C49.20; H.6.03; N,4.41 %), m/z 317.0939. C 1 H 19 NO 6 S requires M + 317.0933 The following compound was prepared according to the general method of Description 14: 5-(l^,3,6-Tetrahydropyridine-l-sulphonyl)-2-methoxybenzoic acid NMR δ (CDCI3) 2.20 (2H, bm), 3.20 (2H, t J = 6Hz), 3.60 (2H, m), 4.15 (3H, s), 5.55- 5.85 (2H, m), 7.20 (IH, d, J = 9Hz), 8.00 (IH, dd, J<lHz, 9Hz), 8.55 (IH, d, J<lHz). Description 15 5-BenzylsuIphonyl-2-methoxybenzoic acid To a stirred solution of sodium sulfite (17.64g, 0.14 mol) and sodium hydrogen carbonate (25.8g, 0.3 mol) in water (250 ml) at 67° C was added 5-chlorosulphonyl-2- methoxybenzoic acid (25.05g, 0.1 mol) portionwise over 5 minutes. After a further 3 hours at 65°C MeOH (100 ml) and benzyl chloride (13.8 ml, 0.12 mol) were added sequentially and the mixture stirred at 65° C for a further 20 hours, cooled and poured into water (2L). The aqueous solution was washed with CH2CI2 (2 x 250ml), acidified with concentrated HC1 and the resultant solid filtered, washed with water and dried to afford the title compound as a white solid (14.07g). NMR δ (CDCI3) 4.00 (3H, s), 4.30 (2H, s), 6.95 (IH, d, J = 9Hz), 7.05-7.35 (5H, m), 7.60 (IH, dd, J = 1Hz, 9Hz), 8.30 (IH, d, J = 1Hz). The following compound was prepared by the general method of Description 15: 5-IsopropylsuIphonyl-2-methoxybenzoic acid NMR δ (CDCI3) 1.30 (6H, d, J=6Hz), 3.20 (IH, m), 7.20 (IH, d, J = 9Hz), 8.10 (IH, dd, J = 1Hz, 9Hz), 8.60 (IH, d, J = 1Hz). Description 16 2-(3,5-Dibromo-2-methoxyphenyl)-lH-pyrrole Prepared from 3,5-dibromo-2-hydroxybenzoic acid by reaction with dimethylsulphate followed by conversion to the acid chloride and finally reaction according to the method of Kruse et al., (Heterocycles, 26, 3141, 1987). NMR δ (CDCI3) 3.75 (3 H, s), 6.32 (1 H, m), 6.60 (1 H, m), 6.93 (1 H, m), 7.49 (1 H, d, J = 2 Hz), 7.65 (1 H, d, J = 2 Hz), 9.63 (1 H, br s). Description 17 2-(3-Bromo-5-ethylsulphonyl-2-methoxyphenyl)-lH-pyrrole Prepared from 5-ethylsulphonyl-2-methoxybenzoic acid by reaction with bromine and 49% hydrogen bromide in acetic acid to give 3-bromo-5-ethylsulphonyl-2-hydroxybenzoic acid, followed by reaction with dimethylsulphate, conversion to the acid chloride using thionyl chloride and finally reaction by the method of Kruse et al (Heterocycles, 26, 3141, 1987). NMR δ (CDCI3) 1.3 (3 H, t J = 7 Hz), 3.2 (2 H, q, J = 7 Hz), 3.8 (3 H, s), 6.35 (1 H, m), 6.75 (1 H, m), 6.95 (1 H, m), 7.9 (1 H, d, J = 7 Hz), 8.05 (1 H, d, J = 7 Hz), 9.6 (1 H, br s). Description 18 2-(2-Methoxy-5-phenylsuIphonylphenyl)-lH-pyrroIe (a) Phenylsulphonyl chloride (17.7 g, 100 mmol) was added dropwise at ambient temperature to a stirred solution of methyl salicylate (15.2 g, 100 mmol) and triethylamine (14 ml, 100 mmol) in dichloromethane (300 ml). After 2 h the mixture was evaporated in vacuo and the residue partitioned between ether and water. The organic layer was washed with water, dried (Na2SO4) and evaporated in vacuo. The crude material was purified by chromatography on silica gel using ether - pentane to afford 2- phenylsulphonyloxybenzoic acid methyl ester. NMR δ (CDCI3) 3.8 (3 H, s), 7.0 - 8.0 (8 H, m). (b) 2-Phenylsulphonyloxybenzoic acid methyl ester (20.3 g, 69.5 mmol) and aluminium chloride (18.6 g, 139 mmol) were stirred together at 140°C for 1.25 h. The mixture was allowed to cool and stirred with concentrated HCl (150 ml) and ice (50 g). The product was extracted into dichloromethane (3 x 200 ml) and the combined extracts dried (Na2SO4) and evaporated in vacuo. The residue was dissolved in AR acetone (250 ml) and potassium carbonate (19.2 g, 139 mmol) added. To this mixture was added dimethyl sulphate (13 ml, 137 mmol) dropwise and the resultant mixture heated at reflux for 21 h. The cooled mixture was filtered and the filter cake washed with fresh acetone. Combined filtrates were evaporated in vacuo and the residue treated with water (250 ml) and NaOH (40%; 12.7 ml). The mixture was heated at reflux for 3 h. The solution was cooled and washed with dichloromethane. The aqueous layer was acidified with concentrated HCl and extracted with dichloromethane (2 x 150 ml). Combined extracts were dried (Na2SO4) and evaporated in vacuo to give 2-methoxy-5-phenylsulphonylbenzoic acid (8.8g) NMR δ (CDCI3) 4.1 (3 H, s), 7.15 (2 H, d, J = 8 Hz), 7.4 - 7.7 (3 H, m), 7.95 (2 H, m), 8.2 (1 H, dd, J = 8 Hz, 2 Hz), 8.65 (1 H, d, J = 2 Hz). (c) The product of part (b) was reacted with thionyl chloride and the resulting acid chloride further reacted according to the method of Kruse et al., (Heterocycles, 26, 3141, 1987) to give the title compound NMR δ (CDCI3) 4.0 (3 H, s), 6.3 (1 H, m), 6.75 (1 H, m), 6.9 (1 H, m), 7.0 (1 H, d, J = 8 Hz), 7.4 - 7.6 (3 H, m), 7.7 (1 H, dd, J = 8 Hz, 2 Hz), 7.95 (2 H, dd, J = 8 Hz, 2 Hz), 8.2 (1 H, d, J = 2 Hz), 9.7 (1 H, br s). Example 1 2-(5-EthylsulphonyI-2-methoxyphenyl)-5-(l-(2-(R,S)-phenylpiperidinyl)-methyl)-lH- pyrrole, oxalate To a solution of 2-phenylpiperidine (0.14g) (prepared as described by C.G. Overberger, J.Org.Chem., 27, 417 (1962)) in ethanol (20ml) was added formaldehyde (0.07ml of a 37- 40% aqueous solution). This was stirred at room temperature for 0.5h before adding glacial acetic acid (0.07ml) and stirring continued for a further lOmin. A solution of 2-(5- ethylsulphonyl-2-methoxyphenyl)-lH-pyrrole (0.19g, C.G. Kruse et al., Heterocycles, vol 26, 3141, 1987) in ethanol (3.3ml) was added and the mixture stirred at room temperature for 72h. The solvent was removed in vacuo, the residue chromatographed on silica gel with 5% methanol-dichloromethane as eluant and the pure fractions combined. The free base was dissolved in dichloromethane and one equivalent of oxalic acid in dichloro¬ methane was added. This solution was evaporated in vacuo to give the title compound as a pink foam, 0.06g (17%). m.p. 107-110° *H NMR (CDC1 3 ) δ: 1.29 (3H, t, J=7Hz), 1.45-1.70 (IH, br m), 1.75-2.27 (4H, br m), 2.41-2.74 (2H, br m), 3.15 (2H, q, J=7Hz), 3.40-3.53 (IH, br d, J=13Hz), 3.62-3.73 (IH, d, J=13Hz), 3.73-3.86 (IH, d, J=13Hz), 4.00 (3H, s), 4.27-4.41 (IH, d, J=13Hz), 6.25 (IH, m), 6.63-6.74 (IH, m), 7.06 (IH, d, J=7Hz), 7.37-7.64 (5H, br m), 7.64-7.78 (IH, dd, J=8,2Hz), 8.25 (IH, d, J=2Hz), 11.37-11.53 (IH br s) The following compound was prepared according to the general method of Example 1: (a) 2-(5-N,N-Diethylaminosulphonyl-2-methoxyphenyl)-5-[l-(2-(R )- phenylazacycloheptyl)methyI]-lH-pyιτoIe mp 94-96°C, /z 495.2540. C2 H 7 N3θ 3 S requires M + 495.2556. *H NMR (CDCI3) δ: 1.13 (6H, t, J=7 Hz), 1.50 - 2.00 (7H, broad m), 2.75 (IH, m), 2.98 (IH, m), 3.23 (4H, q, J=7 Hz), 3.47-3.58 ( 2H, J=14.5 Hz), 3.73 (IH, t, J=6 Hz), 4.05 (3H, s), 6.00 (IH, t J=3 Hz), 6.56 (IH, J=3 Hz), 7.01 (IH, d, J=9 Hz), 7.23 (2H, t, J=7 Hz), 7.33 (2H, t, J=6 Hz), 7.45 (2H, d, J=7 Hz), 7. 55 (IH, dd, J=7 Hz), 7.99 (IH, d, J=3 Hz) and 9.70 (IH, broad s). Example 2 2-(5-Ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R,S)-phenylpyrrolidinyl)-methyl)- lH-pyrrole, oxalate To a solution of of 2-phenylpyrrolidine (0.882g, 0.6 mmol ) (prepared as described by J.L.Seeman Synthesis 498 (1977)) in ethanol (10 ml) was added, at 0°C, 0.5 g of aqueous formaldehyde (30-40% aqueous solution). This was allowed to warm to room temperature for 0.5 h before adding glacial acetic acid 0.5 g and stirred for a further 10 min. A solution of 2-(5-ethylsulphonyl-2-methoxy)-lH-pyrrole (lg, 0.4 mmol) in ethanol (20 ml) was added and the reaction was stirred for a further 24 h. The reaction was then concentrated in vacuo to a gum which partitioned between dichloromethane and saturated aqueous potassium carbonate. The organic layer was separated and dried over sodium sulphate and concentrated in vacuo to a gum which was chromatographed on silica using a gradient of 3-5% methanol in dichloromethane. The major product of the reaction eluted in 5% methanol in dichloromethane and was concentrated in vacuo to a gum (0.98 g; 59% from the pyrrole). The oxalate salt was prepared by adding to an ethereal solution one equivalent of oxalic acid in ether. When a solution in acetone was concentrated in high vacuum, it gave the title compound as a pale green foam. !H NMR (d 6 .DMSO) δ: 1.05 (3H, t, J=7 Hz), 2.05 (4H, m, ), 3.2 (IH, m, ), 3.3 (2H, q, J=7 Hz), 3.4 (IH, m.), 4.0 (3H, s), 4.15 (2H, s), 4.35 (IH, m), 6.2 (IH, m), 6.75(1H, m) 7.2-7.5 (6H, m) 7.5 (IH, m, dd J=7 Hz, J=lHz), 7.95 (IH, d, J=l Hz), 11.55 (IH, s). Example 3 2-(5-Ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R )-phenylazacycloheptyl)-methyl)- lH-pyrrole, hydrochloride To a solution of 2-(R,S)-phenylazacycloheptane (0.6 g, 3.43 mmol) [prepared from caprolactam as described by B. E. Maryanoff et al. J. Med. Chenu, 30, 1433 (1987)] in ethanol (5 ml) was added formaldehyde (0.27 ml of a 37-40% aqueous solution). This was stirred at room temperature for 0.5 h before adding glacial acetic acid (0.25 ml) and stirring was continued for a further 10 min. 2-(5-Ethylsulphonyl-2-methoxy)-lH-pyrrole (0.6 g, 2.26 mmol) was added in one portion, and the mixture stirred at room temperature for 18 h. The solvent was removed in vacuo, and the residue was dissolved in dichloro¬ methane and washed with aqueous potassium carbonate solution. The organic fraction was dried over anhydrous potassium carbonate, and chromatographed on silica gel with 1% methanol-dichloromethane as eluant and the pure fractions combined, and evaporated in vacuo to give the free base which was dissolved in chloroform and shaken with 2N hydrochloric acid. The chloroform layer was dried over sodium sulphate and evaporated to dryness in vacuo. The residue was triturated with ether to give the title compound as an off-white slightly hygroscopic solid, (0.65 g; 59 %), mp 142-144°C. (Found: C, 62.67; H, 6.54; N, 5.66. C26H32N2O3S.HCI.O.5H2O requires: C, 62.69; H, 6.88; N, 5.62%.) The hydrochloride salt was dissolved in dichloromethane and shaken with aqueous potassium carbonate solution, washed with water, dried over anhydrous potassium carbonate and evaporated to dryness in vacuo. The residue was triturated with ether- pentane, and dried in vacuo, to give the free base as a foam. IH NMR (CDCI3) δ: 1.19 (3H, t J=7 Hz), 1.40-1.90 (8H, br m), 2.72 (IH, m), 2.91 (IH, m) 3.02 (2H, q, J=7 Hz), 3.43 (IH, d, J=14 Hz), 3.53 (IH, d, J=14 Hz), 3.66 (IH, m), 4.00 (3H, s), 5.93 (IH, t J=3 Hz), 6.52 (IH, m), 7.01 (IH, d, J=9 Hz), 7.24 (IH, m), 7.26 (2H, m),7.38 (2H, m), 7.55 (IH, m), 7.99 (IH, d, J=2 Hz), and 9.6 (IH, br. s). The following compounds were prepared according to the general method of Example 3: (a) 2-(5-Ethylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R )-(4- methylphenyl)azacydoheptyl)methyl]-lH-pyrrole, hydrochloride Found: C, 62.95; H, 6.88; N, 5.38. C27H34N2O3S. HCl. 0.5 H 2 O requires: C, 63.33; H, 7.09; N, 5.47%, m/z (Cl) 465 (M-H+, 3%), 280 (8), 190 (100). (b) 2-(5-Ethylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R )-( - methoxyphenyl)azacycloheptyl)methyl]-lH-pyrrole, hydrochloride Found: C, 61.01; H, 6.77; N, 5.21. C27H34N2O4S. HCl. 0.5 H 2 O requires C, 61.40; H, 6.87; N, 5.30 %, m/z 482 (M+, 5%), 205 (40), 162 (100), 148 (62) (c) 2-[2-Methoxy-5-(l-pyrroIidinyl)sιrtphonyIphenyl]-5-[l-(2-(R,S)- phenylazacycIoheptyl)methyI]-lH-pyrrole Found: C, 66.00; H, 6.82; N, 8.42. C2gH35N3θ3S 0.75 H 2 0 requires C, 66.31 ; H, 7.25; N, 8.29% , m/z 493.2363. C2 8 H3 5 N3O 3 S requires M+ 493.2398. !H NMR (CDCI3) δ: 1.5-1.7 (4H, m,), 1.70 - 2.00 (8H, broad m), 2.75 (IH, m), 2.98 (IH, m), 3.23 (4H, q, J=7 Hz), 3.48-3.62 (2H, J=14.5 Hz), 3.73 (IH, t, J=6 Hz), 4.05 (3H, s), 6.00 (IH, t, J=3 Hz), 6.56 (IH, t, J=3 Hz), 7.01 (IH, d, J=9 Hz), 7.23 (IH, t J=7 Hz), 7.33 (2H, t, J=6 Hz), 7.45 (2H, d, J=7 Hz); 7.55 (IH, dd, J=7 Hz); 7.99 (IH, d, J=3 Hz), and 9.70 (IH, broad s). (d) 2-(2-Methoxy-5-(4-morpholinyl)sulphonyIphenyl)-5-[l-(2-(R^)- phenylazacycloheptyl)methyl]-lH*pyrroIe Found: C, 64.96; H, 6.70; N,8.09. C2 8 H35N 3 O4S .O.5H2O requires C, 64.84; H, 7 .00; N, 8.10% m/z 509.2330. C2 8 H 35 N3O S requires M+ 509.2347. IH NMR (CDCI3) δ: 1.5-1.7 (5H, m), 1.70-2.00 (4H, broad m), 2.75 (IH, m), 2.98 (5H, m), 3.48-3.62 (2H, dd, J=14.5 Hz), 3.73 (4H, t, J=6 Hz), 4.05 (3H, s), 6.00 (IH, t, J=3 Hz), 6.56 (IH, t J=3 Hz), 7.01 (IH, d, J=9 Hz), 7.23 (IH, t, J=7 Hz), 7.33 (2H, t, J=6 Hz), 7.45 (3H, d, J= 7 Hz), 7.90 (IH, d, J=3 Hz), and 9.70 (IH, broad s). Example 4 2-(3^-Dibromo-2-methoxyphenyl)-5-(l-(2-(R,S)-phenylazacycloheptyl)-methyl)-lH- pyrrole, hydrochloride A solution of 2-(R,S)-phenylazacycloheptane (0.48 g, 2.74 mmol), 37% aqueous formaldehyde (0.215 ml) and glacial acetic acid (0.2 ml) was treated with 2-(3,5-dibromo- 2-methoxyphenyl)-lH-pyrrole (0.6 g, 1.807 mmol) as described for Example 3, to give the tide compound as a slightly hygroscopic white solid, (0.345 g; 33%), mp 135-138 °C. Example 5 2-(2-Methoxy-5-N,N-dimethylaminosulphonylphenyl)-5-[l-(2-(R )- phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride A solution of 2-(R,S)-phenylazacycloheptane (0.35 g, 2.0 mmol), 37% aqueous formaldehyde (0.20 ml) and glacial acetic acid (0.12 ml ) was treated with 2-(2-methoxy- 5-N,N-dimethylaminosulphonylphenyl)-lH-pyrrole (0.54 g, 2.0 mmol) as described in Example (1) to give the free base of the title compound as a pink foam. A solution in chloroform was shaken with dilute hydrochloric acid (2 ml), separated, dried over sodium sulphate, and evaporated to dryness in vacuo to give the title compound as an off-white powder (0.34g; 38% ), mp 145-150°C, (Found: C, 59.86; H, 6.42; N, 8.14. C26H33N3O3S.HCI.O.8.H2O requires C, 60.23; H, 6.92; N, 8.10%), /z 467.2275 C26H33N3O3S requires M + 467.2245 The following compound was prepared according to the general method of Example 5: (a) 2-[5-(l-Aze<idinylsulphonyI)-2-methoxyphenyl]-5-[l-(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole mp 66-67 °C (ether) (Found: C, 67.31; H, 6.83; N, 8.78. C27H33N3O3S requires C, 67.61; H, 6.93; N, 8.76 %), m/z 479.2220 C27H33N3O3S requires M+ 479.2265 Example 6 2-(3-Bromo-5-ethylsulphonyl-2-methoxyphenyl 5-(l-(2-(R,S)-phenylazacycloheptyl)- methyl)-lH-pyrrole, hydrochloride A solution of 2-(R,S)-phenylazacycloheptane (0.29 g, 1.66 mmol), 37% aqueous formaldehyde (0.16 ml) and glacial acetic acid (0.1 ml) was treated with 2-(3-bromo-5- ethylsulphonyl-2-methoxyphenyl)-lH-pyrrole (0.41 g, 1.2 mmol) as described for Example 3, except the reaction was heated at 40°C for 4 days, to give the tifle compound as an off-white solid, (0.12 g; 18%). Example 7 2-(3-Bromo-5-ethylsιdphonyl-2-methoxyphenyI)-5-(l-(2-(R,S)- phenylazacycloheptyI)methyl)-lH-pyrrole, oxalate Phosphoryl chloride (0.22 ml) was added dropwise to N-formyl-2-(R,S)- phenylazacycloheptane (0.41g) at 0°C, under argon, and the reaction mixture was stirred at room temperature for 0.5 h. 1,2-Dichloroethane (23 ml) was added and the solution cooled (ice/salt) before adding a solution of 2-(3-bromo-5-ethylsulphonyl-2- methoxyphenyl)-lH-pyrrole (0.41g) in 1,2-dichloroe thane (11 ml) dropwise. The reaction mixture was stirred at room temperature for 18 h, and then cooled (ice/water) and sodium borohydride (0.54g) was added portion wise. The mixture was stirred at room temperature for 2.5 h. The excess hydride was decomposed by dropwise addition of water (3.5 ml) and methanol (3.5 ml). The mixture was partitioned between water and dichloromethane and extracted into further dichloromethane. The combined organic layers were washed with sodium carbonate solution, dried (sodium sulphate), evaporated to dryness in-vacuo and chromatographed on silica, eluting with 1% methanol/dichloromethane. The product was treated with oxalic acid in ether to afford the title compound as an off-white solid (0.31 g; 42%), mp 94-96°C. J H NMR (d 6 -DMSO, 80°C) δ: 1.13 (3H, t, J=8 Hz), 1.46 - 2.01 (8H, broad m), 2.85 - 3.24 (2H, m), 3.35 (2H, q, J=8 Hz), 3.71 (3H, s), 3.75 (2H, s), 4.00 (IH, t, J=5 Hz), 6.10 (IH, broad s), 6.68 (IH, t, J=2 Hz), 7.15 - 7.52 (5H, m), 7.82 (IH, d, J=2 Hz), 7.98 (IH, d, J=2 Hz), and 10.80 (IH, broad s). The following compounds were prepared according to the general method of Example 7: (a) 2-[5-(bis-(2-Methoxyethyl))aminosulphonyl-2-met_hoxyphenyl]-5-(l-(2-(R )- phenylazacycloheptyl)methyl)-lH-pyrrole, oxalate sintered at 58-60°C. Found: C, 58.61; H, 6.43; N, 6.25. C3oH4iN O5S.-1.2 (C2H2O4) requires, C, 58.63; H, 6.59; N, 6.33 %. (b) 2-{5-[(N-Ethyl-N-2-methoxyethyl)aminosuIphonyl]-2-methoxyphenyl)}-5-[l-(2- (R,S)-phenylazacycloheptyl)methyl]-lH-pyrrole mp 104-105°C. (Found: C, 66.04; H, 7.36; N, 8.12. C29H39N3O4S requires C, 66.26; H.7.48; N.7.99 %), /z 525.2685. C29H39N3O4S requires M+ 525.2660. Examples 8a and 8b 2-(3-Bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R)- phenylazacycloheptyl)methyl)-lH-pyιτole (E8a) and 2-(3-Bromo-5-ethylsulphonyl-2- methoxyphenyl)-S-(l-(2-(S)-phenylazacycloheptyl)meflιyl)-lH-pyrrole (E8b) The tifle compounds were prepared from the free base of Example 7 (26 mg) by HPLC [Gilson autoprep HPLC system with a Chiralpak AD (250 x 20mm) column and 2.5/97.5 ethanol-hexane plus 0.1% diethylamine as eluant at lOml/min] The faster enantiomer (E8a) (12.8 mg) had a retention time of 38min, [α] 20 £> -74.75° (c 0.99% in chloroform), ee >98% by HPLC on Chiralpak AD column, with hexane/ethanol as the eluant The slower enantiomer (E8b) (13.7 mg) had a retention time of 45min, [α] 20 D +65.35°, (c 0.98 in chloroform), ee >98.2% by HPLC on Chiralpak AD column, hexane/ethanol as the eluant. Example 9 2-(3-Bromo-5-ethylsulphonyI-2-methoxyphenyl 5-(l-(2-(S)- phenylazacycloheptyl)methyl)-lH-pyrroIe, oxalate The title compound (0.34g; 45%) was also prepared from l-formyl-2-(S)- phenylazacycloheptane (0.41 g) and 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-lH- pyrrole (0.41 g) using a procedure similar to that of Example 7, mp 89-91°C, [α]^£> + 28.4° (c, 0.76% in chloroform), ee 99.0% by HPLC on a Chiralpak AD column using hexane/ethanol as the eluant, X H NMR (d 6 -DMSO) δ: 1.15 (3H, t, J=7 Hz), 1.45 - 2.15 (8H, broad m), 2.98 - 3.13 (IH, broad m), 3.20 - 3.32 (IH, broad m), 3.40 (2H, q, J=7 Hz), 3.68 (3H, s), 3.84 (2H, broad s), 4.18 (IH, broad s), 6.20 (IH, broad s), 6.75 (IH, broad s), 7.25 - 7.34 (IH, m), 7.38 (2H, t, J=7 Hz), 7.51 (2H, d, J=7 Hz), 7.87 (IH, d, J=2 Hz), 8.01 (IH, d, J=2 Hz), and 11.30 - 11.44 (IH, broad s). Example 10 2-(5-Ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R)-phenylazacycloheptyl)methyl)- lH-pyrrole, oxalate To a solution of 2-(R)-phenylazacycloheptane (0.29 g) in ethanol (4 ml) was added formaldehyde (0.13 ml of a 37-40% aqueous solution). After 0.5 h, glacial acetic acid (0.13 ml) was added and stirring was continued for a further 10 min before adding a solution of 2-(5-ethylsulphonyl-2-methoxyphenyl)-lH-pyrrole [C. G. Kruse et al, Heterocycles, 26, 3141 (1987)] (0.36g) in ethanol (6 ml). This mixture was stirred at room temperature for 18 h. The solution was evaporated to dryness in vacuo and the residue was chromatographed on silica, eluting with ethyl acetate/pentane (1:1). Crystallisation from ether afforded the tifle compound as a pale grey solid (0.22 g; 27%). mp 94-96°C, [CC] 20 D -7.3° (c 1.0% in ethanol), ee 98.7% by HPLC on a Chiralpak AD column using hexane/ethanol as the eluant !H NMR (d 6 -DMSO) δ: 1.10 (3H, t, J=7 Hz), 1.43 - 2.18 (8H, broad m), 2.98 - 3.13 (IH, broad m), 3.25 (2H, q, J=7 Hz), 3.25 (IH, broad s), 3.77 - 3.88 (2H, broad s), 3.97 (3H, s), 4.10 - 4.24 (IH, broad s), 4.40 - 6.00 (2H, broad s), 6.17 (IH broad s), 6.69 (IH, t J=3 Hz), 7.32 (2H, t J=8 Hz), 7.42 (2H, t J=8 Hz), 7.54 (2H, d, J=8 Hz); 7.66 (IH, dd, J=8,2 Hz), 8.00 (IH, d, J=2 Hz), and 11.07 - 11.21 (IH, broad s). Example 11 2-(5-EthyIsulphonyl-2-methoxyphenyl 5-(l-(2-(S)-phenylazacyclohept l)mettιyl)-lH- pyrrole, oxalate The title compound was prepared from 2-(S)-phenylazacycloheptane (0.35 g, 2 mmol) and 2-(5-ethylsulphonyl-2-methoxyphenyl-lH-pyrrole (0.33 g, 1.33 mmol) by the method of Example 10, as needles, mp 90-92°C, ee 92.4% by HPLC on a Chiralpak AD column using hexane/ethanol as the eluant. Example 12 2-(2-Methoxy-5-(l-piperidinyl)suIphonylphenyl)-5-[l-(2-(R,S)- phenylazacydoheptyl)methyl]-lH-pyrrole, oxalate Phosphoryl chloride (0.33 ml, 0.54 g, 3.5 mmol) was added dropwise to l-formyl-2-(R,S)- phenylazacycloheptane (0.65 g, 3.2 mmol) at 0°C under argon, and the mixture was stirred at room temperature for 0.5 h. 1,2-Dichloroethane (20 ml) was added and the solution was cooled (ice/salt) before adding a solution of 2-(5-(l-piperidinyl)sulphonyl-2- methoxyphenyl)-lH-pyιrole (0.5 g, 1.6 mmol) in 1,2 -dichloroethane (20 ml), dropwise. The mixture was stirred at room temperature for 18 h and then cooled to 0°C (ice), and sodium borohydride (0.66 g) was added, portionwise. The mixture was stirred at room temperature for 2 h. The excess hydride was decomposed by dropwise addition of methanol (5 ml) and water (10 ml). The mixture was partitioned between water and dichloromethane and the aqueous fraction was further extracted with dichloromethane. The combined organic fractions were dried (sodium sulphate), evaporated to dryness in vacuo, and chromatographed on silica gel, eluting with hexane, followed by hexane/ether (1:1) to afford the free base of the title compound (0.7 g) (86%) as an oil. This was dissolved in ether and treated with a solution of oxalic acid (0.12 g; 1 equiv ) in ether to give the title compound as a colourless crystalline solid, (0.37 g), mp 96-98°C, (Found: C, 61.37; H, 6.34; N, 6.81. C29H37N3O3S.C2H2O4.O.6H2O requires C, 61.22; H, 6.61; N, 6.91%). Example 13 2-(2-Methoxy-5-(4-morpholinyl)sulphonylphenyl)-5-(l-(2-(R)- phenylazacycloheptyl)mettiyl)-lH-pyrrole, oxalate Phosphoryl chloride (0.18 ml) was added dropwise to N-formyl-2-(R)-phenylaza- cycloheptane (0.34 g) at 0°C under argon, and the mixture was stirred at room temperature for 0.5 h. 1,2-Dichloroethane (20 ml) was added and the solution was cooled (ice/salt) before adding a solution of the 2-(2-methoxy-5-(4-morpholinyl)sulphonylphenyl)-lH- pyrrole (0.32 g) in 1,2-dichloroethane (9 ml) dropwise. This mixture was stirred at room temperature for 18 h. The reaction was cooled (ice/water) and sodium borohydride (0.45 g) added portion-wise. The mixture was stirred at room temperature for 2.5 h. The excess hydride was decomposed by dropwise addition of water (2.9 ml) and methanol (2.9 ml). This mixture was partitioned between water and dichloromethane and extracted into further dichloromethane. The combined organic layers were dried (sodium sulphate), evaporated to dryness in vacuo and chromatographed on silica, eluting with 1% methanol dichloromethane. The free base was treated with oxalic acid in ether to give the tifle compound as an off-white solid (0.37g, 62%), mp 107-109°C (ether), ee 97.6% by HPLC on a Chiralpak AD column using hexane/ethanol as the eluant The following compounds were prepared according to the general method of Example 13: (a) 2-(2-Methoxy-5-(4-morpholinyl)suphonylphenyl)-5-(l-(2-(S)-phenyl- azacycloheptyl)methyl)-lH-pyrrole, oxalate mp 108- 109°C (ether), ee 97.8% by HPLC on a Chiralpak AD column using hexane/ethanol as the eluant H NMR (d 6 -DMSO) δ: 1.49 - 1.85 (6H, broad m), 1.85 - 2.19 (2H, broad m), 2.85 (4H, broad s), 2.99 - 3.15 (IH, broad m), 3.20 - 3.34 (IH, broad m), 3.63 (4H, broad s), 3.85 (2H, broad s), 3.98 (3H, s), 4.12 - 4.24 (IH, broad s), 6.16 (IH, broad s), 6.66 (IH, t, J=4 Hz), 7.25 - 7.35 (2H, m), 7.40 (2H, t, J=7 Hz), 7.53 (3H, d, J=7 Hz), 7.83 (IH, d, J=2 Hz), 11.11 - 11.21 (IH, broad s). (b) 2-(2-Methoxy-5-N,N-di-n-propylaminosuphonylphenyl)-5-(l-(2-(R)-phenyl- azacycloheptyl)methyl)-lH-pyrrole, oxalate mp 80-82°C, [α] 20 D + 20.0° (c, 0.69% in methanol) (c) 2-(2-Methoxy-5-N,N-di-n-propylaminosuphonylphenyl)-5-(l-(2-(S)- phenylazacydoheptyl)methyl)-lH-pyrrole, oxalate mp 75-76°C, [α] 20 D -4.6° (c 0.22% in chloroform), ee 96.2% by HPLC on a Chiralpak AD column using hexane/ethanol as the eluant Example 14 2-(2-Methox -5-N,N-di-n-propylaminosulphonylphenyl)-5-[l-(2-(R^)- phenylazacyclohept l)methyl]-lH-pyrrole Phosphoryl chloride (0.28 ml; 3.0 mmol) was added dropwise to N-formyl-2-(R,S)- phenylazacycloheptane (0.57 g; 2.8 mmol) at 0°C under argon, and then stirred at room temperature for 0.5 h. 1,2-Dichloroethane (20 ml) was added and the solution was cooled (ice/salt) before adding a solution of 2-(2-methoxy-5-N,N-di-n- propylaminosulphonyl)phenyl)-lH-pyrrole (0.5 g, 15 mmol) in 1,2 -dichloroethane (20 ml), dropwise. The mixture was stirred at room temperature for 18 h. The reaction mixture was cooled to 0°C (ice) and sodium borohydride (0.66 g) was added portionwise. The mixture was stirred at room temperature for 2 h. The excess hydride was decomposed by dropwise addition of methanol (5 ml) and water (10 ml). The mixture was partitioned between water and dichloromethane and me aqueous fraction was further extracted with dichloromethane. The combined organic fractions were dried (sodium sulphate), evaporated to dryness in vacuo, and chromatographed on silica gel, eluting with hexane, followed by hexane/ether (1:1) to afford the free base of the tifle compound (0.64 g) (82%), mp 116-119°C. Found: C, 69.17; H, 7.95; N, 8.19. C 30 H 41 N3θ3S requires C, 68.80; H, 7.89; N, 8.02%., m/z 523.2896, C30H41N3O3S requires M+ 523.2867 Example 15 2-(2-Methoxy-5-(4-thiomorpholinyl)sulphonylphenyl)-5-[l-(2-(R^)- phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride Phosphoryl chloride (0.30 ml; 0.505 g; 3.3 mmol) was added dropwise to N-formyl-2- (R,S)-phenylazacycloheptane (0.676 g; 3.3 mmol) at 0°C under argon, and the mixture was stirred at room temperature for 0.5 h. 1,2-Dichloroethane (20 ml) was added and the solution was cooled (ice/salt) before adding a solution of 2-(2-methoxy-5-(4- thiomorpholinyl)sulphonylphenyl)-lH-pyrrole (0.75 g; 2.2 mmol) in 1,2 -dichloroethane (20 ml), dropwise. The mixture was stirred at room temperature for 18 h and then cooled to 0°C (ice), and sodium borohydride (0.84 g) was added portionwise. The mixture was stirred at room temperature for 4 h. The excess hydride was decomposed by dropwise addition of methanol (10 ml) and water (20 ml). The mixture was partitioned between water and dichloromethane and the aqueous fraction was further extracted with dichloromethane. The combined organic fractions were dried (sodium sulphate), evaporated to dryness in vacuo. The product was dissolved in methanol (5ml) cooled in ice and concentrated HCl (3ml) was added. The mixture was stirred at room temperature for 2 h. Water (50 ml) was added and the mixture was basified with 10% sodium carbonate and extracted with dichloromethane. The organic extract was dried (sodium sulphate) and evaporated to dryness in vacuo. The product was chromatographed on silica gel, eluting with ether/dichloromethane (2:1) to afford the free base of the title compound (0.8 g) (68%) as an oil. A portion (0.7 g) of the product was dissolved in chloroform and then shaken with 0.5 N hydrochloric acid. The organic phase was dried (sodium sulphate) and evaporated to dryness in vacuo to afford a semi-solid which was triturated with ether to afford the title compound (0.72 g), mp 128-135°C, (Found: C, 59.49; H, 6.47; N, 7.50. C28H35N3O3S2.HCI requires C, 59.82; H, 6.45; 7.47 %), m/z 525. C28H35N3O3S2 requires M + 525. The following compounds were prepared according to the general method of Example 15: (a) 2-(5-Benzylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)-phenylazacycloheptyl) methyl]-lH-pyrrole, hydrochloride Found C, 65.41, H, 6.21, N, 5.05%; C31H34N2O3S.HCLH2O requires C, 65.41, H, 6.55, N, 4.92%. (b) 2-(5-__sopropylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrroIe, hydrochloride Found C, 63.18, H, 6.97, N, 5.55%; C27H34N2O3S.HCI.O.5H2O requires C, 63.32, H, 7.09, N, 5.47%. (c) 2-(2-Methoxy-5-phenylsιdphonylphenyl)-5-[l-(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride Found C, 65.00, H, 6.17, N, 5.15%; C30H32N2O3S.HCl.H2O requires C, 64.91, H, 6.36, N, 5.05%. (d) 2-[5-(l,2,3,6-Tetrahydropyridine-l-sulphonyl)-2-methoxyphenyl]-5-[l-(2-(R )- phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride NMR δ (CDCI3) 1.30-2.90 (10H, m), 2.95-3.70 (6H, m), 3.80-5.10 (6H, m), 5.55-5.85 (2H, m), 6.05-6.25 (IH, m), 6.50 (IH, m), 7.05 (IH, ra), 7.30-7.80 (6H, m), 7-95 (IH, dd, JklHz, 9Hz), 11.40 (IH, bs), 11.85-12.30 (IH, m). (e) 2-(2-Methoxy-5-N,N-dimethylaminosuIphonylphenyl)-5-[l-(2-(R,SH4- fluorophenyI)azacycloheptyl)methyl]-lH-pyrτoIe, hydrochloride Found: C, 59.79; H, 6.38; N, 7.59. C26H32FN3O3S. HCl requires C, 59.82; H, 6.37; N, 8.05 %, m/z 485.2170, C26H32FN3O3S requires M+ 485. 2196 (f) 2-(3-Bromo-5-ethylsulphonyl-2-methoxyphenyI)-5-[l-(2-(R,S)-(4- fluorophenyl)azacycloheptyl)methyϊ]-lH-pyrrole, hydrochloride IH NMR δ: 1.34 (3H, t, J=8 Hz), 1.80 - 2.19 (8H, m), 2.32 (m) and 2.46 (m) (together IH), 2.72 (m) and 3.09 (m) (together IH), 3.15 - 3.40 (2H, m), 3.67 (IH, m), 3.79 (s) and 3.88 (s) (together 3H), 4.25 (IH, m), 4.00 (m) and 5.05 (m) (together IH), 6.10 (broad s) and 6.23 (broad s)(together IH), 6.62 (t, J=3 Hz) and 6.67 (t, J=3 Hz) (together IH), 7.14 (IH, t J=9 Hz), 7.20 (IH, t, J=9 Hz), 7.48 (IH, m), 7.73 (IH, m), 7.95 (IH, t J=2 Hz), 8.12 (IH, m), 11.38 (broad s) and 11.85 (broad s) (together IH), 11.75 (broad s) and 12.12 (broad s)(together IH), m/z 548.1153, C 2 6H3()Br F N 2 O 3 S requires M+ 548. 1173 Example 16 2-(5-EthyIsulphonyl-2-methoxyphenyl)-5-(l-(2-(R)-phenylpiperidinyl)methyl)-lH- pyrrole To a solution of 2-(R)-phenylpiperidine (0.27 g) in ethanol (4 ml) was added formaldehyde (0.13 ml of a 37-40% aqueous solution). After 0.5 h, glacial acetic acid (0.13 ml) was added and stirring was continued for a further 10 min before adding a solution of 2-(5-ethylsulphonyl-2-methoxyphenyl)-lH-pyrrole (0.36 g) in ethanol (6 ml). This mixture was stirred at room temperature for 7 days, and then evaporated to dryness in vacuo and the residue was chromatographed on silica, eluting with 2% methanol/dichloromethane. Trituration with methanol afforded the title compound as a pink solid (0.31 g, 51%), mp 187-188°C, [α] 20 D -92.4° (c 1.0% in chloroform). J H NMR (CDCI3) δ: 1.28 (3H, t, J=7 Hz), 1.32 - 1.45 (IH, broad m), 1.52 - 1.85 (5H, broad m), 2.05 - 2.20 (IH, broad t J=l 1 Hz), 3.10 (5H, q, J=7 Hz), 3.68 (IH, d, J=15 Hz), 4.08 (3H, s), 6.00 (IH, t, J=3 Hz), 6.60 (IH, t J=3 Hz), 7.08 (IH, d, J=8 Hz), 7.27 (IH, t, J=7 Hz), 7.34 (2H, t, J=7 Hz), 7.42 (2H, d, J=7 Hz), 7.65 (IH, dt, J=8,2 Hz), 8.08 (IH, d, J=2 Hz), and 9.54 - 9.68 (IH, broad s). The following compound was prepared according to the general method of Example 16: (a) 2-(5-Ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(S)phenylpiperidinyl)methyl)-lH- pyrrole Prepared from 2-(S)-phenylpiperidine. mp 187-188°C, [α] 20 D +97.4° (c 0.63% in chloroform), *H NMR (CDCI3) δ: 1.27 (3H, t J=8 Hz), 1.32 - 1.45 (IH, broad m), 1.52 - 1.73 (3H, broad m), 1.73 - 1.84 (2H, broad m), 2.13 (IH, dt J=ll,3 Hz), 3.04 - 3.18 (5H, m), 3.67 (IH, d, J=15 Hz), 4.08 (3H, s), 6.00 (IH, t J=3 Hz), 6.60 (IH, t J=3 Hz), 7.07 (IH, d, J=9 Hz), 7.26 (IH, t J=5 Hz), 7.35 (2H, t J=8 Hz), 7.42 (2H, d, J=7 Hz), 7.64 (IH, dt, J=9,2 Hz), 8.06 (IH, d, J=2 Hz), and 9.52 - 9.63 (IH, broad m). Example 17 (-)-2-(5-EthylsulphonyI-2-methoxyphenyl)-5-(l-(2-phenyIpyrrolidinyI)methyI)-lH- pyrrole, oxalate To a solution of (+)-2-phenylpyrrolidine (0.124 g) in ethanol (2 ml) was added formaldehyde (0.066 ml of a 37-40% aqueous solution). After 0.5 h glacial acetic acid (0.066 ml) was added and stirring was continued for a further 10 min before adding a solution of 2-(5-ethylsulphonyl-2-methoxyphenyl)-lH-pyrrole (0.18 g) in ethanol (3 ml). The mixture was stirred at room temperature for 12 days, and then evaporated to dryness in vacuo and the residue was chromatographed on silica, eluting with 2% methanol/ dichloromethane. The product was treated with oxalic acid in ether to give the tifle compound as a pale brown solid (0.082 g; 23%), mp 88-89°C, [α] 20 D -35.3° (c 0.57% in chloroform), ee 97.6% by HPLC on a Chiralpak AD column using hexane/ethanol as the eluant !H NMR (d 6 -DMSO) δ: 1.23 (3H, t, J=7 Hz), 2.00 - 2.25 (3H, broad s), 2.37 - 2.73 (2H, broad m), 3.08 - 3.28 (IH, broad m), 3.14 (2H, q, J=7 Hz), 3.53 (IH, broad m), 4.10 (3H, s), 4.20 (IH, d, J=14 Hz), 4.37 (IH, broad s), 6.35 (IH, broad s), 6.8 (IH, broad s), 7.37 - 7.70 (6H, m), 7.80 (IH, dd, J=8,2 Hz), 8.10 (IH, d, J=2 Hz), 11.34 - 11.49 (IH, broad s). The following compound was prepared from (-)-2-phenylpyrrolidine according to the general method of Example 17: (a) (+)-2-(5-Ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-phenylpyrrolidinyl)methyl)-lH- pyrrole, oxalate mp 96-98°C Example 18 The following compounds were also prepared by the general methods exemphfied above: (a) 2-(5-dimethylaminosulphonyl-2-methoxy-3-methylphenyl)-5-[ 1 -(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride Found: C, 61.82; H, 6.94; N, 7.86; C27H35N3O3S. HCl. 0.5H 2 O requires C, 61.52; H, 7.08; N, 7.97% (b) 2-(3-chloro-5-dimethylaminosulphonyl-2-methoxyphenyl)-5-[ 1 -(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride. Found: C, 57.83; H, 5.88; N, 7.91; C26H32CIN3O3S.HCI requires C, 57.99; H, 6.18; N, 7.80% (c) 2-(5-dimethylaminosulphonyl-2-methoxy-3-trifluoromethylphenyl)-5-[l-(2- (R,S)-phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride. Found: C, 56.72; H, 5.63; N, 7.34; C27H32F3N3O5.HCI requires C, 56.69; H, 5.81; N, 7.35% (d) 2-(2,3-dimethoxy-5-ethylsulρhonylρhenyl)-5-[l-(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride. m /z 482.2238. C27H34N2O4S requires M+ 482.2273 (e) 2-(3-tert-butyl-5-dimethylaminosulphonyl-2-methoxyphenyl)-5-[ 1 -(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride. m /z 523.2854. C30H41N3O3S requires M+ 523.2867 (f) 2-(5-ethylsulphonyl-3-ethylthio-2-methoxyphenyl)-5-[l-(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, mp 133.5-136.5°C. Found: C, 65.36; H, 6.75; N, 5.49; C28H36N2O3S2 requires C, 65.59; H, 7.08; N, 5.46% (g) 2-(2,3-dimethoxy-5-dimethylaminosulphonylphenyl)-5-[l-(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride. NMR δ (CDCI3): 1.30-2.60 (8H, m), 2.70-2.90 (7H, m), 3.00-3.80 (3H, m), 3.85-4.10 (6H, m), 4.15-5.05 (IH, m), 6.05-6.25 (IH, m), 6.50-6.65 (IH, m), 7.05 (IH, d, J=2Hz), 7.30-7.55 (4H, m), 7.55-7.65 (IH, m), 7.75 (IH, m), 11.20-11.45 (IH, m), 11.80-12.20 (IH, m) (h) 2-(3-tert-butyl-5-ethylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride. Found: C, 65.12; H, 7.27; N, 5.13; C30H40N2O3S.HCI. 0.5H 2 O requires C, 65.02; H, 7.46; N, 5.05% (i) 2-(5-bromo-2,3-dimethoxyphenyl)-5-[l-(2-(R,S)-phenylazacycloheptyl)methyl]- lH-pyrrole, hydrochloride m /z (m-l+) 467.1357 C25H28N2θ2Br requires 467.1333 (j) 2-[(2,3-dihydro-5-dimethylaminosulphonyl)benzofuran-7-yl]-5-[l-(2-(R,S)- ρhenylazacycloheptyl)methyl]-lH-pyrrole, hydrochloride. NMR δ (CDCI3) 1.30-2.60 (7H, m), 2.75 (6H, s), 2.90-3.40 (2H, m), 3.30 (2H, t J=8Hz), 3.40-4.00 (2H, m), 4.20 (IH, m), 4.70-5.05 (3H, m), 6.05-6.25 (IH, m), 6.55 (IH, m), 7.30-7.55 (5H, m), 7.65- 7.85 (2H, m), 11.20-11.55 (IH, m), 11.80-12.25 (IH, m) ' (k) 2-{5-[(N-isopropyl-N-methyl)aminosulphonyl]-2-methoxyphenyl}-5-[l-(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole, oxalate m.p. 95-98°C observed M + = 495.2568 C 28 H 37 N 3 O,-.S requires 495.2581. (1) 2- { 5-[(N-cyclopropyl-N-methyl)aminosulphonyl]-2-methoxyphenyl } -5-[ 1 -(2- (R,S)-phenylazacycloheptyl)methyl]-lH-pyrrole, oxalate m.p. 97-98°C (m) 2- { 3-bromo-5-[(N,N-dimethylaminosulphonyl]-2-memoxyphenyl } -5-[ 1 -(2-(R,S)- phenylazacycloheptyl)methyl]-lH-pyrrole m.p.49-51°C. Found: C, 57.28; H, 5.89; N, 7.69. C26H32BrN 3 O3S requires C, 57.14; H, 5.90; N, 7.69%. (n) 2-(5-Nitro-2-methoxyphenyl)-5-( l-(2-(R,S)-phenylazacycloheptyl)methyl)- 1H- pyrrole, mp 129-130°C. Found: C, 70.59; H, 6.66; N, 10.42; C24H27N3O3. 0.25H2O requires C, 70.31 ; H, 6.76; N, 10.25% (0) 2-(5-Ethylsulfonyl-2-methoxyphenyl)-5-( l-(2-(R,S)-(4- methylphenyl)pyrrolidinyl)methyl)-lH-pyrrole, hydrochloride. Found: C, 60.91; H, 6.44; N, 5.67; C25H30N2O3S. HCl.H 2 O requires C, 60.90; H, 6.75; N, 5.68% DATA The ability of the compounds to bind selectively to human D3 dopamine receptors can be demonstrated by measuring their binding to cloned receptors. The inhibition constants (Kj) of test compounds for displacement of iodosulpride binding to human D2 and D3 dopamine receptors expressed in CHO cells have been determined. The cell lines were shown to be free from bacterial, fungal and mycoplasmal contaminants, and stocks of each were stored frozen in liquid nitrogen. Cultures were grown as monolayers or in suspension in standard cell culture media. Cells were recovered by scraping (from monolayers) or by centrifugation (from suspension cultures), and were washed two or three times by suspension in phosphate buffered saline followed by collection by centrifugation. Cell pellets were stored frozen at -40°C. Crude cell membranes were prepared by homogenisation followed by high-speed centrifugation, and characterisation of cloned receptors achieved by radioligand binding. Preparation of CHO cell membranes Cell pellets were gently thawed at room temperature, and resuspended in about 20 volumes of ice-cold 50 mM Tris salts (pH 7.4 @ 37°C), 20mM EDTA, 0.2 M sucrose. The suspension was homogenised using an Ultra-Turrax at full speed for 15 sec. The homogenate was centrifuged at 18,000 r.p.m for 20 min at 4°C in a Sorvall RC5C centrifuge. The membrane pellet was resuspended in ice-cold 50 mM Tris salts (pH 7.4 @ 37°C), using an Ultra-Turrax, and recentrifuged at 18,000 r.p.m for 15 min at 4°C in a Sorvall RC5C. The membranes were washed two more times with ice-cold 50 mM Tris salts (pH 7.4 @ 37°C). The final pellet was resuspended in 50 mM Tris salts (pH 7.4 @ 37°C), and the protein content determined using bovine serum albumin as a standard (Bradford, M. M. (1976) Anal. Biochem. 72, 248-254). Binding experiments on cloned dopamine receptors Crude cell membranes were incubated with 0.1 nM [^I] iodosulpride (~2000 Ci/mmol; Amersham, U. K.), and the test compound in a buffer containing 50 mM Tris salts (pH 7.4 @ 37°C), 120 mM NaCl, 5 mM KC1, 2 mM CaCl 2 , 1 mM MgCl 2 , 0.1% (w/v) bovine serum albumin, in a total volume of 1 ml for 30 min at 37°C. Following incubation with the test compound, samples were filtered using a Brandel Cell Harvester, and washed three times with ice-cold 50 mM Tris salts (pH 7.4 @ 37°C), 120 mM NaCl, 5 mM KC1, 2 mM CaCl2, 1 mM MgCl2. The radioactivity on the filters was measured using a Cobra gamma counter (Canberra Packard). Non-specific binding was defined as the radioligand binding remaining after incubation in the presence of 100 μM iodosulpride. For competition curves, 14 concentrations (half-log dilutions) of competing cold drug were used. Competition curves were analysed simultaneously whenever possible using non-linear least-squares fitting procedures, capable of fitting one, two or three site models. The compounds of Examples 3, 6, 7, 8, 10 ,11 and 13 had IC50 values of between 1 and 50 nM at the human D3 receptor. Pharmaceutical Formulations The following represent typical pharmaceutical formulations according to the present invention, which may be prepared using standard methods. IV Infusion Compound of formula (I) 1-40 mg Buffer to ρH ca 7 Solvent complexing agent to 100 ml Bolus Injection Compound of formula (I) 1-40 mg Buffer to pH ca 7 Co-Solvent to 5 ml Buffer : Suitable buffers include citrate, phosphate, sodium hydroxide/hydrochloric acid. Solvent : Typically water but may also include cyclodextrins ( 1 - 100 mg) and co-solvents such as propylene glycol, polyethylene glycol and alcohol. Tablet Compound 1 - 40 mg Diluent/Filler * 50 - 250 mg Binder 5 - 25 mg Disentegrant * 5 - 50 mg Lubricant 1 - 5 mg Cyclodextrin 1 - 100 mg * may also include cyclodextrins Diluent : e.g. Microcrystalline ceUulose, lactose, starch Binder : e.g. Polyvinylpyrrolidone, hydroxypropymethylcellulose Disintegrant : e.g. Sodium starch glycoUate, crospovidone Lubricant : e.g. Magnesium stearate, sodium stearyl fumarate. Oral Suspension Compound 1 - 40 mg Suspending Agent 0.1 - 10 mg Diluent 20 - 60 mg Preservative 0.01 - 1.0 mg Buffer to pH ca 5 - 8 Co-solvent or solubiliser 0 - 40 mg Flavour 0.01 - 1.0 mg Colourant 0.001 - 0.1 mg Suspending agent : e.g. Xanthan gum, microcrystalline cellulose Diluent : e.g. sorbitol solution, typically water Preservative : e.g. sodium benzoate Buffer : e.g. citrate Co-solvent : e.g. alcohol, propylene glycol, polyethylene glycol Solubiliser: e.g. cyclodextrin

Claims: Claims A compound of formula (I) : formula (I) wherein Rl represents Cj^alkyl; and R 2 , R3, R4 and R^ each independently represent hydrogen, halogen, Cj^alkyl, Cι_4alkoxy, Cι_4alko yCι_4alkyl, Cj^alkylsulphonyl, trifluoromethylsulphonyl; optionally substituted arylsulphonyl, optionally substituted heteroarylsulphonyl, optionally substituted aralkylsulphonyl, optionally substituted heteroaralkylsulphonyl, nitro, cyano, amino, mono- or di-alkylamino, trifluoromethyl, trifluoromethoxy, hydroxyl, hydroxyalkyl, C^alkylthio, Ci^alkanoyl, Cι_4alkoxycarbonyl, or -SO2NR^R^ wherein R^ and R? each independently represent hydrogen, Cj^alkyl or Cj^alkoxyCi^alkyl, or NR6R7 forms a 3- to 8- membered fully saturated heterocyclic ring, a 5- to 8-membered partially saturated heterocyclic ring, or a 5- to 8-membered fully saturated heterocyclic ring which contains in addition to the nitrogen atom an oxygen or sulphur atom; or Rl and R 2 together form a linking chain -(CH2) m Op; (wherein m is 2 to 4 and p is zero or 1) which chain may be optionally substituted by one or two Cι_4al yl groups; and Y represents a group of formula : (a) wherein R8 and R^ independently represent hydrogen, C^galkyl, optionally substituted arylCj.galkyl or optionally substituted heteroarylCi.βalkyl; R!0 represents an optionally substituted aryl or optionally substituted heteroaryl group; and Z represents -(CH2) n wherein n is 2 to 8 or -(CH2)qCH=CH(CH2) r where q and r independently represent 1 to 3; or a salt thereof. 2. A compound according to claim 1 wherein R represents methyl or ethyl. 3. A compound according to claim 1 or claim 2 wherein at least one of R 2 to R5 is hydrogen, and the other substituents are selected from halogen, Cι_2alkyl, Cι_2alkoxy, Cμ4alkylsulphonyl, phenylsulphonyl, benzylsulphonyl and -S02NR6R7 wherein R^ and R? represent Cι_4alkyl or Cι_2 lkoxyCι_2al yl, or NR6R7 represents a ring selected from azetidinyl, pyrrolidinyl, piperidinyl, azacycloheptyl, 1,2,3,6- tetrahydropyridinyl, 4-morpholinyl or 4-thiomorpholinyl. 4. A compound according to any of claims 1 to3 wherein R* represents hydrogen and R^ represents hydrogen or methyl. 5. A compound according to any of claims 1 to 4 wherein Z represents where the sum of q and r is 2 or 6. A compound according to any of claims 1 to 5 wherein RlO represents optionally substituted phenyl. 7. A compound according to any of claims 1 to 6 wherein the group Y represents 2-phenylpyrrolidinyl, 2-phenylpiperidinyl, 2-phenylazacycloheptyl or 2- phenylazacyclooctyl. 8. A compound according to any one of claims 1 to 7 in which the carbon atom bearing R*0 is of the R configuration. 9. A compound according to claim 1 selected from: 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-( 1 -(2-(R,S)-phenylazacycloheptyl)-methyl)- 1H- pyrrole, 2-(2-methoxy-5-N,N-dimethylaminosulphonylphenyl)-5-[l-(2-(R,S)-phenylazacyclo- heptyl)methyl]- lH-pyrrole, 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R,S)-phenylazacycloheptyl)- methyl)- lH-pyrrole, 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R)-phenylazacycloheptyl)methyl)-lH- pyrrole, 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(S)-phenylazacycloheptyl)methyl)-lH- pyrrole, 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(R)-phenylazacycloheptyl)- methyl)- lH-pyrrole, 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-(l-(2-(S)-phenylazacycloheptyl)- methyl)-lH-pyrrole, 2-(2-methoxy-5-dimethylaminosulphonylphenyl)-5-[ 1 -(2-(R,S)-(4-fluorophenyl)- azacycloheptyl)methyl]-lH-pyrrole, 2-(3-bromo-5-ethylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)-(4-fluorophenyl)- azacycloheptyl)methyl]-lH-pyrrole, 2-(5-ethylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)-(4-methylphenyl)azacycloheptyl)- methyl]- lH-pyrrole), 2-(2-methoxy-5-(4-morpholinyl)sulphonylphenyl)-5-[l-(2-(R,S)-phenylazacycloheptyl)- methyl]- lH-pyrrole, 2-(2-methoxy-5-(4-mo holinyl)sulphonylphenyl)-5-(l-(2-(R)-phenylazacycloheptyl)- methyl)- lH-pyrrole, 2-(2-methoxy-5-(4-morpholinyl)suphonylphenyl)-5-(l-(2-(S)-phenylazacycloheptyl)- methyl)- 1 H-pyrrole, 2-[5-(azetidinylsulphonyl)-2-methoxyphenyl]-5-[l-(2-(R,S)-phenylazacycloheptyl)- methyl]-lH-pyrrole, and 2-(5-isopropylsulphonyl-2-methoxyphenyl)-5-[l-(2-(R,S)-phenylazacycloheptyl)methyl]- lH-pyrrole, or a salt thereof. 10. A process for preparing a compound of formula (I) as defined in any of claims 1 to 9 which process comprises : (a) carrying out a Mannich reaction with a compound of formula (II) : Formula II (wherein R*-R5 are as hereinbefore defined), and an amine of formula (III) : Formula in wherein R*0 and Z are as hereinbefore defined; (b) carrying out a Vilsmeier reaction with a compound of formula (II) and an amide of formula (TV) : Formula (IV) wherein R^, R! and Z are as hereinbefore defined; and reducing the intermediate product with, for example, sodium borohydride or cyanoborohydride; c) to prepare a compound of formula (I) in which R^ and R^ both represent hydrogen, reductive amination of a compound of formula (V) : Formula (V) with an amine of formula (HI); and optionally thereafter forming a salt of formula (I). 10. A method of treating a condition which requires modulation of dopamine D3 receptors, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) or a physiologically acceptable salt thereof. 11. The use of a compound of formula (I) or a physiologically acceptable salt thereof in the manufacture of a medicament for the treatment of a condition which requires modulation of dopamine D3 receptors. 12. A pharmaceutical composition comprising a compound of formula (I) or a physiologicaUy acceptable salt thereof and a physiologically acceptable carrier.

Inventors: JOHNSON CHRISTOPHER NORBERT, MARKWELL ROGER EDWARD, STEMP GEOFFREY, WADSWORTH HARRY JOHN, WATTS ERIC ALFRED, JOHNSON, CHRISTOPHER, NORBERT, MARKWELL, ROGER, EDWARD, STEMP, GEOFFREY, WADSWORTH, HARRY, JOHN, WATTS, ERIC, ALFRED
Applicants: JOHNSON CHRISTOPHER NORBERT, MARKWELL ROGER EDWARD, SMITHKLINE BEECHAM PLC, STEMP GEOFFREY, WADSWORTH HARRY JOHN, WATTS ERIC ALFRED, JOHNSON, CHRISTOPHER, NORBERT, MARKWELL, ROGER, EDWARD, STEMP, GEOFFREY, WADSWORTH, HARRY, JOHN, WATTS, ERIC, ALFRED
Application year: 1994
Main classification: C07D403
IPC codes: A61K31, A61P43, C07D207, C07D401, C07D403, C07D405